

10/506,459

=> d his

(FILE 'HOME' ENTERED AT 12:42:37 ON 09 AUG 2007)

FILE 'REGISTRY' ENTERED AT 12:42:55 ON 09 AUG 2007

L1 STRUCTURE UPLOADED
L2 10 S L1
L3 564 S L1 SSS FUL
L4 493 S L3 AND CAPLUS/LC
L5 71 S L3 NOT L4


FILE 'CAPLUS' ENTERED AT 12:44:29 ON 09 AUG 2007

L6 12 S L3

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> d ibib abs hitstr total

ANSWER 1 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:652002 CAPLUS

DOCUMENT NUMBER: 147:132924

TITLE: 3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: An insight into the criteria for selectivity

AUTHOR(S): Dessalew, Nigus; Bharatam, Prasad V.

CORPORATE SOURCE: Department of Pharmaceutical Chemistry, School of Pharmacy, Addis Ababa University, Addis Ababa, 1176, Ethiopia

SOURCE: European Journal of Medicinal Chemistry (2007), 42(7), 1014-1027

CODEN: EJMCAS; ISSN: 0223-5234

PUBLISHER: Elsevier Masson SAS

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Selective glycogen synthase kinase 3 (GSK3) inhibition over cyclin dependent kinases such as cyclin dependent kinase 2 (CDK2) and cyclin dependent kinase 4 (CDK4) is an important requirement for improved therapeutic profile of GSK3 inhibitors. The concepts of selectivity and additivity fields have been employed in developing selective CoMFA models for these related kinases. Initially, sets of three individual CoMFA models were developed, using 36 compds. of bisarylmaleimide series to correlate with the GSK3, CDK2 and CDK4 inhibitory potencies. These models showed a satisfactory statistical significance: CoMFA-GSK3 (r^2 con, r^2 cv: 0.931, 0.519), CoMFA-CDK2 (0.937, 0.563), and CoMFA-CDK4 (0.892, 0.725). Three different selective CoMFA models were then developed using differences in pIC_{50} values. These three models showed a superior statistical significance: (i) CoMFA-Selective1 (r^2 con, r^2 cv: 0.969, 0.768), (ii) CoMFA-Selective 2 (0.974, 0.835) and (iii) CoMFA-Selective3 (0.963, 0.776). The selective models were found to outperform the individual models in terms of the quality of correlation and were found to be more informative in pinpointing the structural basis for the observed quant. differences of kinase inhibition. An in-depth comparative investigation was carried out between the individual and selective models to gain an insight into the selectivity criterion. To further validate this approach, a set of new compds. were designed which show selectivity and were docked into the active site of GSK3, using FlexX based incremental construction algorithm.

IT 603266-87-1 603267-72-7 603269-03-0
603269-09-6 603269-15-4 603269-32-5
603269-40-5 603269-52-9 603281-31-8
603281-60-3 603281-90-9 603282-02-6
603282-27-5 603282-94-6 603283-31-4
603283-91-6 603284-08-8 603287-46-3
603291-82-3 603292-11-1 603310-08-3
687635-00-3 735262-27-8 743417-56-3
744195-11-7 754183-54-5 754183-55-6
768357-81-9 769918-88-9 773846-58-5
786639-53-0 848483-40-9 848483-43-2
943769-65-1


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(3D-QSAR and mol. docking study on bisarylmaleimide series as GSK3, CDK2 and CDK4 inhibitors: selectivity)

RN 603266-87-1 CAPLUS


10/506,459

CN 1H-Pyrrole-2,5-dione, 3-pyrazolo[1,5-a]pyridin-3-yl-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)




RN 603267-72-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[1-(3-hydroxypropyl)-1H-indol-4-yl]-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)



RN 603269-03-0 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(7-benzofuranyl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)



10/506,459


RN 603269-09-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(4-benzofuranyl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)




RN 603269-15-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1,3-benzodioxol-5-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)



RN 603269-32-5 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-benzo[b]thien-7-yl-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)



10/506,459


RN 603269-40-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1,3-benzodioxol-4-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)




RN 603269-52-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(2,3-dihydro-7-benzofuranyl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)




RN 603281-31-8 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603281-60-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(1-piperidinyl)carbamate- (9CI) (CA INDEX NAME)




RN 603281-90-9 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide, 7-[4-(7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-N,N-dimethyl- (CA INDEX NAME)




RN 603282-02-6 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
dihydro-N,N-dimethyl- (CA INDEX NAME)




RN 603282-27-5 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
7-[4-(1,3-benzodioxol-4-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-
dihydro-N,N-dimethyl- (CA INDEX NAME)



RN 603282-94-6 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 603283-31-4 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 2-acetyl-7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

10/506,459




RN 603283-91-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(2-acetyl-1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-4-(1,3-benzodioxol-4-yl)- (CA INDEX NAME)




RN 603284-08-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(2-acetyl-1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-4-(2,3-dihydro-7-benzofuranyl)- (CA INDEX NAME)




RN 603292-11-1 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-2,5-dioxo-4-pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603310-08-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyridin-3-yl-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)




RN 687635-00-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 2-acetyl-7-(4-furo[3,2-c]pyridin-7-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 735262-27-8 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyrimidin-3-yl-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)



RN 743417-56-3 CAPLUS


10/506,459

CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyrazin-3-yl-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)




RN 744195-11-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-b]pyridazin-3-yl-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)




RN 754183-54-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-4-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)




RN 754183-55-6 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(4-furo[3,2-c]pyridin-7-yl-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 768357-81-9 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-furo[3,2-c]pyridin-7-yl-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)



RN 769918-88-9 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
 7-(4-furo[3,2-c]pyridin-7-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
 dihydro-N,N-dimethyl- (CA INDEX NAME)




RN 773846-58-5 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(4-furo[3,2-c]pyridin-7-yl)-2,5-
 dihydro-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(4-
 morpholinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 786639-53-0 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(4-furo[3,2-c]pyridin-7-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(1-oxopropyl)-(9CI) (CA INDEX NAME)



RN 848483-40-9 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(2-acetyl-1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-4-(7-benzofuranyl)- (CA INDEX NAME)

10/506,459




RN 848483-43-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-c]pyrimidin-3-yl-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)



RN 943769-65-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



10/506,459

REFERENCE COUNT:

47

THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

16 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1212983 CAPLUS

DOCUMENT NUMBER: 146:134590

TITLE: Investigation of potential glycogen synthase kinase 3 inhibitors using pharmacophore mapping and virtual screening

AUTHOR(S): Dessalew, Nigus; Bharatam, Prasad V.

CORPORATE SOURCE: Department of Pharmaceutical Chemistry, School of Pharmacy, Addis Ababa University, Addis Ababa, Ethiopia

SOURCE: Chemical Biology & Drug Design (2006), 68(3), 154-165

CODEN: CBDDAL; ISSN: 1747-0277

PUBLISHER: Blackwell Publishing Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Glycogen synthase kinase-3 is a serine/threonine kinase that has attracted significant drug discovery attention in recent years. To investigate the identification of new potential glycogen synthase kinase-3 inhibitors, a pharmacophore mapping study was carried out using a set of 21 structurally diverse glycogen synthase kinase-3 inhibitors. A hypothesis containing four features: two hydrophobic, one hydrogen bond donor and another hydrogen bond acceptor was found to be the best from the 10 common feature hypotheses produced by HipHop module of Catalyst. The best hypothesis has a high cost of 156.592 and higher best fit values were obtained for the 21 inhibitors using this best hypothesis than the other HipHop hypotheses. The best hypothesis was then used to screen electronically the NCI2000 database. The hits obtained were docked into glycogen synthase kinase-3 β active site. A total of five novel potential leads were proposed after: (i) visual examination of how well they dock into the glycogen synthase kinase-3 β -binding site, (ii) comparative anal. of their FlexX, G-Score, PMF-Score, ChemScore and D-Scores values, (iii) comparison of their best fit value with the known inhibitors and (iv) examination of the how the hits retain interactions with the important amino acid residues of glycogen synthase kinase-3 β -binding site.


IT 603287-46-3

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmacophore mapping and virtual screening of potential glycogen synthase kinase 3 inhibitors)

RN 603287-46-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-b]pyridazin-3-yl-4-[1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (CA INDEX NAME)



REFERENCE COUNT:

58

THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:817890 CAPLUS

DOCUMENT NUMBER: 145:230524

TITLE: Preparation of maleimide derivatives, pharmaceutical compositions and methods for treatment of cancer

INVENTOR(S): Li, Chiang J.; Ashwell, Mark Antony; Hill, Jason; Moussa, Magdi M.; Munshi, Neru

PATENT ASSIGNEE(S): Arqule, Inc., USA

SOURCE: PCT Int. Appl., 133pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006086484	A1	20060817	WO 2006-US4456	20060209
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM US 2006223760 A1 20061005 US 2006-350335 20060209 PRIORITY APPLN. INFO.: US 2005-650951P P 20050209 OTHER SOURCE(S): MARPAT 145:230524 GI				



I



II

AB Title compds. I [R¹-3 independently = H, halo, (un)substituted alkyl, etc.; R⁴ = H, alkyl, CH₂R⁷; R⁵ and R⁶ independently = H or alkyl; R⁷ = aminocarboxylic acid group, peptide, OP(=O)(OH)₂, OP(=O)(OH)(O-alkyl), OP(=O)(O-alkyl)₂, etc.; Q = aryl, heteroaryl, aryloxy, etc.; X = CH₂, S, O, NHR⁸; R⁸ = H, (un)substituted alkyl, cycloalkyl, etc.; Y = CH₂ or bond; m = 1 or 2], and their pharmaceutically acceptable salts, are prepared and

disclosed as antitumor agents. Thus, e.g., II was prepared by cyclocondensation of 2-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-2-oxoethanoic acid Me ester (preparation given) with indole-3-acetamide followed by reduction. In bioassays for antitumor activity, II was found to possess an IC50 value of 2.89 with colon cancer and 4.04 with breast cancer. The present invention also relates to pharmaceutical compns. comprising pyrroloquinolinyl-pyrrole-2,5-dione compds. and pyrroloquinolinyl-pyrrolidine-2,5-dione compds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or pyrroloquinolinyl-pyrrolidine-2,5-dione compound of the present invention.


IT 905854-68-4P 905854-69-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of maleimide derivs., pharmaceutical compns. and methods for treatment of cancer)

RN 905854-68-4 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid, 7-[2,5-dihydro-4-(1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 905854-69-5 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid, 3,4-dihydro-7-[(3R,4R)-4-(1H-indol-3-yl)-2,5-dioxo-3-pyrrolidinyl]-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 905854-70-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of maleimide derivs., pharmaceutical compns. and methods for treatment of cancer)

RN 905854-70-8 CAPLUS

CN 2,5-Pyrrolidinedione, 3-(1H-indol-3-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 4 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:582589 CAPLUS

DOCUMENT NUMBER: 145:432133

TITLE: Orally bioavailable GSK-3 α/β dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo

AUTHOR(S): Kulkarni, Nalini H.; Onyia, Jude E.; Zeng, QingQiang; Tian, Xioayan; Liu, Min; Halladay, David L.; Frolik, Charles A.; Engler, Thomas; Wei, Tao; Kriauciunas, Aidas; Martin, T. John; Sato, Masahiko; Bryant, Henry U.; Ma, Yanfei L.

CORPORATE SOURCE: Lilly Research Laboratories, Eli Lilly & Company, Lilly Corporate Center, Indianapolis, IN, USA

SOURCE: Journal of Bone and Mineral Research (2006), 21(6), 910-920

CODEN: JBMREJ; ISSN: 0884-0431

PUBLISHER: American Society for Bone and Mineral Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB GSK-3, a component of the canonical Wnt signaling pathway, is implicated in regulation of bone mass. The effect of a small mol. GSK-3 inhibitor was evaluated in pre-osteoblasts and in osteopenic rats. GSK-3 inhibitor induced osteoblast differentiation in vitro and increased markers of bone formation in vitro and in vivo with concomitant increased bone mass and strength in rats. Introduction: Inactivation of glycogen synthase kinase-3 (GSK-3) leads to stabilization, accumulation, and translocation of β -catenin into the nucleus to activate downstream Wnt target genes. To examine whether GSK-3 directly regulates bone formation and mass we evaluated the effect of 603281-31-8, a small mol. GSK-3 α/β dual inhibitor in preosteoblastic cells and in osteopenic rats. Materials and Methods: Murine mesenchymal C3H10T1/2 cells were treated with GSK-3 inhibitor (603281-31-8) and assayed for β -catenin levels, activity of Wnt-responsive promoter, expression of mRNA for bone formation, and adipogenic markers and alkaline phosphatase activity. In vivo, 6-mo-old rats were ovariectomized (OVX), allowed to lose bone for 1 mo, and treated with GSK-3 inhibitor at 3 mg/kg/day orally for 60 days. At the end of treatment, BMD was measured by DXA, bone formation rate by histomorphometry, vertebral strength (failure in compression), and the expression levels of osteoblast-related genes by real-time PCR. Results: Treatment of C3H10T1/2 cells with the GSK-3 inhibitor increased the levels of β -catenin accompanied by activation of Wnt-responsive TBE6-luciferase reporter gene. This was associated with an increased expression of mRNA for bone sialoprotein (1.4-fold), collagen $\alpha 1$ (I) (.apprx.2-fold), osteocalcin (1.2-fold), collagen $\alpha 1$ (V) (1.5-fold), alkaline phosphatase (.apprx.160-fold), and runx2 (1.6-fold), markers of the osteoblast phenotype and bone formation activity. Alkaline phosphatase mRNA expression paralleled alkaline phosphatase activity. The mRNA levels of collagens $\alpha 1$ (I), $\alpha 1$ (V), biglycan, osteonectin, and runx-2 increased on treatment with the GSK-3 inhibitor in rat femur compared with the OVX control. DXA analyses revealed significant increases in BMC and BMD in cancellous and cortical bone of OVX rats treated with GSK-3 inhibitor. This was associated with increased strength (peak load, energy, and stiffness) assessed by lumbar vertebra load to failure in compression. Histomorphometric analyses showed that 603281-31-8 robustly increased bone formation but did not exclude a small effect on osteoclasts (resorption). Conclusions: An orally active, small mol. GSK-3 inhibitor induced osteoblast differentiation and increased markers of bone formation in vitro, and increased markers of

10/506,459

bone formation, bone mass, and strength in vivo, consistent with a role for the canonical Wnt pathway in osteogenesis.

REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

16 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:86365 CAPLUS

DOCUMENT NUMBER: 142:336333

TITLE: The development of potent and selective bisarylmaleimide GSK3 inhibitors

AUTHOR(S): Engler, Thomas A.; Malhotra, Sushant; Burkholder, Timothy P.; Henry, James R.; Mendel, David; Porter, Warren J.; Furness, Kelly; Diefenbacher, Clive; Marquart, Angela; Reel, Jon K.; Li, Yihong; Clayton, Joshua; Cunningham, Brian; McLean, Johnathan; O'Toole, John C.; Brozinick, Joseph; Hawkins, Eric; Misener, Elizabeth; Briere, Daniel; Brier, Richard A.; Wagner, Jill R.; Campbell, Robert M.; Anderson, Bryan D.; Vaughn, Renee; Bennett, Donald B.; Meier, Timothy I.; Cook, James A.

CORPORATE SOURCE: Lilly Research Laboratories, Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(4), 899-903

CODEN: BMCLE8; ISSN: 0960-894X


PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:336333

GI



AB Many 3-aryl-4-(1,2,3,4-tetrahydro[1,4]diazepino[6,7,1-hi]indol-7-yl)maleimides exhibit potent GSK3 inhibitory activity (<100 nM IC₅₀), although few show significant selectivity (>100+) vs. CDK2, CDK4, or PKC β II. However, combination of a heteroaryl group with 4-(2-acyl-(1,2,3,4-tetrahydro[1,4]diazepino[6,7,1-hi]indol-7-yl)) group on the maleimide in compds. I [R₁ = imidazo[1,2-a]pyridin-3-yl, pyrazolo[1,5-a]pyridin-3-yl, etc.; R₂ = H, Me₂NCO, morpholin-4-ylcarbonyl, etc.] gave very potent inhibitors of glycogen synthase kinase 3 (GSK3) (≤ 5 nM) with >160 to >10,000-fold selectivity vs. CDK2/4 and PKC β II. These compds. also inhibited tau phosphorylation in cells and were effective in lowering plasma glucose in a rat model of type 2 diabetes (ZDF rat).

IT 603269-03-0P 603269-32-5P 603269-40-5P

603269-52-9P 768357-81-9P 848483-43-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)


(preparation of (diazepinoindolyl)(heteroaryl) maleimides as selective

10/506,459

inhibitors of glycogen synthase kinase 3 and tau phosphorylation and
glucose lowering agents)


RN 603269-03-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(7-benzofuranyl)-4-(1,2,3,4-
tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)




RN 603269-32-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-benzo[b]thien-7-yl-4-(1,2,3,4-
tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)




RN 603269-40-5 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(1,3-benzodioxol-4-yl)-4-(1,2,3,4-
tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)




RN 603269-52-9 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(2,3-dihydro-7-benzofuranyl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)



RN 768357-81-9 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-furo[3,2-c]pyridin-7-yl-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)



RN 848483-43-2 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-c]pyrimidin-3-yl-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)




IT 603267-72-7P 603269-09-6P 603269-15-4P
 603269-45-0P 603269-61-0P 603271-09-6P
 603274-44-8P 603281-31-8P 603281-60-3P
 603281-90-9P 603282-02-6P 603282-27-5P
 603283-31-4P 603283-50-7P 603283-77-8P
 603283-84-7P 603283-91-6P 603283-97-2P
 603284-08-8P 603284-57-7P 603284-65-7P
 603285-14-9P 603287-32-7P 603287-38-3P
 603287-46-3P 603291-10-7P 603291-16-3P
 603291-36-7P 603291-77-6P 603291-82-3P
 603292-11-1P 603294-76-4P 754183-54-5P
 848483-39-6P 848483-40-9P 848483-41-0P
 848483-42-1P 848483-44-3P 848483-45-4P
 848483-46-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of (diazepinoindolyl)(heteroaryl) maleimides as selective inhibitors of glycogen synthase kinase 3 and tau phosphorylation and glucose lowering agents)

RN 603267-72-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[1-(3-hydroxypropyl)-1H-indol-4-yl]-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)




RN 603269-09-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(4-benzofuranyl)-4-(1,2,3,4-


10/506,459

tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)




RN 603269-15-4 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(1,3-benzodioxol-5-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)



RN 603269-45-0 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-benzo[b]thien-4-yl-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)






RN 603281-31-8 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603281-60-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603281-90-9 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
7-[4-(7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-
N,N-dimethyl- (CA INDEX NAME)




RN 603282-02-6 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
dihydro-N,N-dimethyl- (CA INDEX NAME)



RN 603282-27-5 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
 7-[4-(1,3-benzodioxol-4-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-
 dihydro-N,N-dimethyl- (CA INDEX NAME)




RN 603283-31-4 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 2-acetyl-7-(2,5-dihydro-4-
 imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-
 (9CI) (CA INDEX NAME)




RN 603283-50-7 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 603283-77-8 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(4-furo[3,2-c]pyridin-7-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(1-oxopropyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 603283-84-7 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 2-acetyl-7-(4-furo[3,2-c]pyridin-7-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 603283-91-6 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(2-acetyl-1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-4-(1,3-benzodioxol-4-yl)- (CA INDEX NAME)




RN 603283-97-2 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 2-acetyl-7-(4-benzo[b]thien-7-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 603284-08-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(2-acetyl-1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-4-(2,3-dihydro-7-benzofuranyl)- (CA INDEX NAME)




RN 603284-57-7 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
 7-(4-furo[3,2-c]pyridin-7-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
 dihydro-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 603284-65-7 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(4-furo[3,2-c]pyridin-7-yl)-2,5-
 dihydro-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(4-
 morpholinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



RN 603285-14-9 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(4-furo[3,2-c]pyridin-7-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)




RN 603287-32-7 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyrazin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603287-38-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyrazin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603287-46-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-b]pyridazin-3-yl-4-[1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (CA INDEX NAME)




RN 603291-10-7 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyrimidin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603291-16-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyrimidin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603291-36-7 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-c]pyrimidin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603291-77-6 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-2,5-dioxo-4-pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 603291-82-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
7-(2,5-dihydro-2,5-dioxo-4-pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrrol-3-yl)-3,4-
dihydro-N,N-dimethyl- (CA INDEX NAME)




RN 603292-11-1 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-2,5-dioxo-4-
pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(4-
morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603294-76-4 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-[(tetrahydro-2H-pyran-4-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 754183-54-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-4-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)




RN 848483-39-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(3-benzofuranyl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)



RN 848483-40-9 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(2-acetyl-1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-4-(7-benzofuranyl)- (CA INDEX NAME)



10/506,459

RN 848483-41-0 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(imidazo[1,2-a]pyridin-3-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, hydrochloride (9CI)
(CA INDEX NAME)



●x HCl

RN 848483-42-1 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(imidazo[1,2-b]pyridazin-3-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, hydrochloride (9CI)
(CA INDEX NAME)



●x HCl


RN 848483-44-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(imidazo[1,2-a]pyrazin-3-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, hydrochloride (9CI)
(CA INDEX NAME)




● x HCl

RN 848483-45-4 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyrimidin-3-yl-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, hydrochloride (9CI)
 (CA INDEX NAME)



● x HCl

RN 848483-46-5 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-pyrazolo[1,5-a]pyridin-3-yl-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, hydrochloride (9CI)
 (CA INDEX NAME)



●x HCl


IT 603263-27-0P 603265-10-7P 603265-16-3P
 603265-28-7P 603265-36-7P 603265-45-8P
 603266-72-4P 603266-87-1P 603307-92-2P
 603310-08-3P 603312-04-5P 848483-48-7P
 848483-50-1P 848483-51-2P 848483-52-3P
 848483-53-4P 848483-54-5P 848483-55-6P
 848483-56-7P 848483-57-8P 848483-58-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (diazepinoindolyl) (heteroaryl) maleimides as selective inhibitors of glycogen synthase kinase 3 and tau phosphorylation and glucose lowering agents)


RN 603263-27-0 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid, 7-[2,5-dihydro-4-[1-(3-hydroxypropyl)-1H-indol-4-yl]-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603265-10-7 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[4-(4-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603265-16-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[4-(1,3-benzodioxol-5-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-
dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603265-28-7 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-(4-benzo[b]thien-4-yl-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl)-3,4-dihydro-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603265-36-7 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-[4-(2,3-dihydro-7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-
 3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603265-45-8 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-[4-(2,3-dihydro-4-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-
 3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 603266-72-4 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 3,4-dihydro-7-[4-(1,3-dihydro-5-isobenzofuranyl)-2,5-dihydro-2,5-dioxo-1H-
 pyrrol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603266-87-1 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-pyrazolo[1,5-a]pyridin-3-yl-4-(1,2,3,4-
 tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)




RN 603307-92-2 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-(2,5-dihydro-4-imidazo[1,2-a]pyrimidin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-
3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603310-08-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyridin-3-yl-4-(1,2,3,4-
tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)




RN 603312-04-5 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[2,5-dihydro-4-(1H-indol-7-yl)-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 848483-48-7 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-(2,5-dihydro-2,5-dioxo-4-pyrazolo[1,5-a]pyridin-3-yl-1H-pyrrol-3-yl)-3,4-dihydro-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 848483-50-1 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-3,4-dihydro-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 848483-51-2 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-(2,5-dihydro-4-imidazo[1,2-b]pyridazin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-
 3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 848483-52-3 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-[2,5-dihydro-4-(imidazo[1,2-c]pyrimidin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-
 3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 848483-53-4 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-(2,5-dihydro-4-imidazo[1,2-a]pyrazin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 848483-54-5 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[4-(7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 848483-55-6 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[4-(3-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 848483-56-7 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[4-(1,3-benzodioxol-4-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-
dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 848483-57-8 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-(4-benzo[b]thien-7-yl-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl)-3,4-dihydro-
 , 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 848483-58-9 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-[2,5-dihydro-4-(1-methyl-1H-indol-4-yl)-2,5-dioxo-1H-pyrrol-3-yl]-3,4-
 dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT:

37

THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:790823 CAPLUS

DOCUMENT NUMBER: 141:424162

TITLE: Design, Synthesis, and Evaluation of
3,4-Dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as
Inhibitors of Poly(ADP-Ribose) PolymeraseAUTHOR(S): Tikhe, Jayashree G.; Webber, Stephen E.; Hostomsky,
Zdenek; Maegley, Karen A.; Ekkers, Anne; Li, Jianke;
Yu, Xiao-Hong; Almassy, Robert J.; Kumpf, Robert A.;
Boritzki, Theodore J.; Zhang, Cathy; Calabrese, Chris
R.; Curtin, Nicola J.; Kyle, Suzanne; Thomas, Huw D.;
Wang, Lan-Zhen; Calvert, A. Hilary; Golding, Bernard
T.; Griffin, Roger J.; Newell, David R.CORPORATE SOURCE: Pfizer Global RDLA Jolla Laboratories, San Diego, CA,
92121, USASOURCE: Journal of Medicinal Chemistry (2004), 47(22),
5467-5481

CODEN: JMCMAR; ISSN: 0022-2623


PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 141:424162

GI




AB The design, synthesis, and biol. evaluation of potent inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1) are reported. A novel series of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones I [R1 = H, Me, MeCO, PhCHOH, 3-pyrazolyl, H2NCS, etc.; R2 = H, Ph, 4-FC6H4, 2-pyridyl, 3-(Me2NCH2)C6H4, etc.] was designed using a combination of protein structure-based drug design, mol. modeling, and structure-activity relationships (SAR). These novel submicromolar inhibitors possess a tricyclic ring system conformationally restricting the benzamide in the preferred cis orientation. The compds. were designed to optimize space-filling and atomic interactions within the NAD⁺ binding site of PARP-1. Previously described and newly adapted methods were applied to syntheses of these tricyclic inhibitors. Various modifications were made to the diazepinoindolones at the 6- and 7-positions in order to study this region of the active site and optimize noncovalent interactions. The electron d. of I (R1 = HON:CH; R2 = H) bound to chicken PARP-1 revealed that the oxime makes a tight hydrogen bond with the catalytic γ -carboxylate of glutamic acid (Glu) 988 in accordance with our original designs and models. Most of the compds. have been evaluated for inhibition of human PARP-1. Selected inhibitors were also tested for the ability to

potentiate the cytotoxic effect of the DNA-damaging agent Topotecan.
 IT 328542-78-5P 328545-08-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (preparation of disubstituted (dihydro)diazepinoindolones as inhibitors of
 poly(ADP-ribose) polymerase)
 RN 328542-78-5 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepin-1(2H)-one, 3,4-dihydro-6-(2-pyridinyl)-
 (9CI) (CA INDEX NAME)



RN 328545-08-0 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepin-1(2H)-one, 6-(4-fluorophenyl)-3,4-
 dihydro-7-(1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT:

50


THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/506,459


ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:523284 CAPLUS
DOCUMENT NUMBER: 141:225473
TITLE: Preparation of novel aza-1,7-annulated indoles and
their conversion to potent indolocarbazole kinase
inhibitors
AUTHOR(S): Al-awar, Rima S.; Ray, James E.; Hecker, Kyle A.;
Joseph, Sajan; Huang, Jianping; Shih, Chuan; Brooks,
Harold B.; Spencer, Charles D.; Watkins, Scott A.;
Schultz, Richard M.; Considine, Eileen L.; Faul,
Margaret M.; Sullivan, Kevin A.; Kolis, Stanley P.;
Carr, Michael A.; Zhang, Faming
CORPORATE SOURCE: Discovery Chemistry Research, Lilly Research
Laboratories, Eli Lilly and Company, Indianapolis, IN,
46285, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004),
14(15), 3925-3928
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:225473
GI



I



II



III

AB Indolocarbazoles such as I [m = 1, 2; n = 1, 2; R = H, F; R1 = H, F, F3C;
R2 = H, HOCH2; R3 = H, MeSO2, 1-methyl-4-imidazolesulfonyl, H2NCH2CO,
Me2CH (if R3 = H, compds. are present as monohydrochloride salts); X =

(CH₂)_m; Y = (CH₂)_n] with fused saturated nitrogen heterocycles are prepared as kinase inhibitors and tested for their activities against a human colon cancer cell line; I are active antiproliferative agents. E.g., 7-formylindole is reductively aminated with ethanolamine, protected on its sidechain amine with Boc anhydride, converted to its mesylate ester with mesyl chloride, and cyclized with sodium hydride to give diazepinoindole II (R₃ = R₄ = H). II (R₃ = Boc; R₄ = H) is acylated with oxalyl chloride and converted to the Me ester with sodium methoxide to yield II [R₃ = Boc; R₄ = MeO₂CC(:O)]; condensation with 3-indoleacetamide, imide formation, cyclization of the indolocarbazole with palladium (II) acetate, and acid hydrolysis yields I (n = 1; R = R₁ = R₂ = R₃ = H). Conversion of II (R₃ = Boc; R₄ = MeO₂CCO) to the α-ketoamide, reduction of the α-ketoamide to an indoleacetamide, condensation of the indoleacetamide with α-oxoindoleacetic acid esters III (R = H, F; R₁ = H, F, F₃C; R₂ = H, HOCH₂), imide formation, cyclization with palladium acetate, and acid hydrolysis yields I (m = n = 1; R = H, F; R₁ = H, F, F₃C; R₂ = H, HOCH₂). Functionalization of I (m = n = 1; R = R₁ = R₂ = R₃ = H) with sulfonyl chlorides, glycine (with EDC and HOBt as coupling reagents), or acetone in the presence of sodium triacetoxyborohydride yields the N-substituted indolocarbazoles I (m = n = 1; R = R₁ = R₂ = H; R₃ = MeSO₂, 1-methyl-4-imidazolylsulfonyl, H₂NCH₂CO, Me₂CH). The size of the nitrogen heterocycles fused onto the indole nuclei of I have little effect on their antitumor or kinase inhibiting activities.

IT 345262-81-9P 345262-84-2P 345263-27-6P


345263-31-2P 345265-42-1P 748811-06-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation, antitumor and kinase-inhibiting activity, and selectivity of indolocarbazoles fused to saturated nitrogen heterocycles)


RN 345262-81-9 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid, 7-[2,5-dihydro-4-(1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 345262-84-2 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid, 7-[4-(6-fluoro-1H-indol-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 345263-27-6 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-[4-(5,6-difluoro-1H-indol-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-
 3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 345263-31-2 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-[2,5-dihydro-2,5-dioxo-4-[6-(trifluoromethyl)-1H-indol-3-yl]-1H-pyrrol-3-
 yl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 345265-42-1 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[4-(5-fluoro-1H-indol-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-
dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 748811-06-5 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[2,5-dihydro-4-[7-(hydroxymethyl)-6-(trifluoromethyl)-1H-indol-3-yl]-2,5-
dioxo-1H-pyrrol-3-yl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA
INDEX NAME)



L5 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:504435 CAPLUS

DOCUMENT NUMBER: 141:116462

TITLE: Substituted 3-Imidazo[1,2-a]pyridin-3-yl-4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as Highly Selective and Potent Inhibitors of Glycogen Synthase Kinase-3

AUTHOR(S): Engler, Thomas A.; Henry, James R.; Malhotra, Sushant; Cunningham, Brian; Furness, Kelly; Brozinick, Joseph; Burkholder, Timothy P.; Clay, Michael P.; Clayton, Joshua; Diefenbacher, Clive; Hawkins, Eric; Iversen, Philip W.; Li, Yihong; Lindstrom, Terry D.; Marquart, Angela L.; McLean, Johnathan; Mendel, David; Misener, Elizabeth; Briere, Daniel; O'Toole, John C.; Porter, Warren J.; Queener, Steven; Reel, Jon K.; Owens, Rebecca A.; Brier, Richard A.; Eessalu, Thomas E.; Wagner, Jill R.; Campbell, Robert M.; Vaughn, Renee

CORPORATE SOURCE: Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly Company, Indianapolis, IN, 46285, USA

SOURCE: Journal of Medicinal Chemistry (2004), 47(16), 3934-3937

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:116462

AB Glycogen synthase kinase-3 (GSK3) is involved in signaling from the insulin receptor. Inhibitors of GSK3 are expected to effect lowering of plasma glucose similar to insulin, making GSK3 an attractive target for the treatment of type 2 diabetes. Herein we report the discovery of a series of potent and selective GSK3 inhibitors. Some of the compds. show oral activity in an in vivo model of type II diabetes, and others have desirable pharmacokinetic properties.

IT 603281-31-8P 603281-60-3P 603282-02-6P


603285-62-7P 603288-22-8P 722539-09-5P

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation, antidiabetic effect and structure-activity relationship studies of imidazopyridine derivs. as highly selective and potent inhibitors of glycogen synthase kinase-3)


RN 603281-31-8 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603281-60-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603282-02-6 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-3,4-dihydro-N,N-dimethyl- (CA INDEX NAME)




RN 603285-62-7 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
dihydro-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 603288-22-8 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-
a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-9-fluoro-1,2,3,4-tetrahydro-2-(1-
piperidinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 722539-09-5 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[2,5-dihydro-4-(6-methylimidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




IT 603268-64-0P 603272-51-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, antidiabetic effect and structure-activity relationship studies of imidazopyridine derivs. as highly selective and potent inhibitors of glycogen synthase kinase-3)


RN 603268-64-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyridin-3-yl-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 603272-51-1 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(9-fluoro-1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-4-imidazo[1,2-a]pyridin-3-yl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT:

30

THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:737761 CAPLUS

DOCUMENT NUMBER: 139:261331

TITLE: Preparation of 3-(tricyclic fused heteroaryl)
4-heteroaryl substituted 2,5-dioxopyrroles as
GSK-3 β kinase inhibitorsINVENTOR(S): Clayton, Joshua Ryan; Diefenbacher, Clive Gideon;
Engler, Thomas Albert; Furness, Kelly Wayne; Henry,
James Robert; Malhotra, Sushant; Marquart, Angela
Lynn; McLean, Johnathan Alexander; Mendel, David;
Burkholder, Timothy Paul; Li, Yihong; Reel, Jon Kevin

PATENT ASSIGNEE(S): Eli Lilly and Company, USA; et al.

SOURCE: PCT Int. Appl., 161 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003076442	A1	20030918	WO 2003-US5050	20030304
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2477967	A1	20030918	CA 2003-2477967	20030304
AU 2003215325	A1	20030922	AU 2003-215325	20030304
EP 1483265	A1	20041208	EP 2003-711146	20030304
EP 1483265	B1	20061122		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003008243	A	20050111	BR 2003-8243	20030304
US 2005090483	A1	20050428	US 2003-506459	20030304
CN 1639165	A	20050713	CN 2003-805292	20030304
JP 2005526072	T	20050902	JP 2003-574659	20030304
AT 346070	T	20061215	AT 2003-711146	20030304
IN 2004KN01262	A	20060505	IN 2004-KN1262	20040830
PRIORITY APPLN. INFO.:			US 2002-362245P	P 20020305
			WO 2003-US5050	W 20030304
OTHER SOURCE(S):	MARPAT 139:261331			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R1 = H, halo, alkyl; m = 0-4; R = (CH₂)_n, CHMe, CMe₂, CH₂Q1CH₂, CHOHCHOHCH₂; Q1 = CHOH, CO; n = 0-4; WXY = (CH₂)₃, (un)substituted CH₂NHCH₂, NHCOCH₂, etc.; Ar = benzofuryl, benzothienyl, indolyl, etc.], useful for treating GSK-3 β mediated diseases such as


diabetes and Alzheimer's disease, were prepared Thus, treating 3-(6,7-dihydro-6H-[1,4]diazepino[6,7,1-hj]indol-1-yl)-4-(imidazo[1,2-a]pyridin-3-yl)pyrrole-2,5-dione dihydrochloride (preparation given) with di-Ph cyanocarbonimidate in the presence of Et₃N in iso-PrOH followed by addition of morpholine afforded II. The exemplified compds. I exhibit IC₅₀ of $\leq 0.2 \mu\text{M}$ against GSK-2 β . Pharmaceutical composition comprising the compound I was claimed.

IT 603267-94-3P 603269-03-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 3-(tricyclic fused heteroaryl) 4-heteroaryl substituted 2,5-dioxopyrroles as GSK-3 β kinase inhibitors)

RN 603267-94-3 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(7-benzofuranyl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 603269-03-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(7-benzofuranyl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)



IT 603263-19-0P 603263-27-0P 603263-51-0P
603263-74-7P 603263-99-6P 603264-20-6P

603265-10-7P 603265-16-3P 603265-23-2P
603265-28-7P 603265-36-7P 603265-45-8P
603265-64-1P 603265-94-7P 603266-02-0P
603266-09-7P 603266-72-4P 603266-79-1P
603266-87-1P 603267-01-2P 603267-08-9P
603267-24-9P 603267-32-9P 603267-72-7P
603267-87-4P 603268-01-5P 603268-28-6P
603268-35-5P 603268-50-4P 603268-64-0P
603268-86-6P 603269-09-6P 603269-15-4P
603269-24-5P 603269-32-5P 603269-40-5P
603269-45-0P 603269-52-9P 603269-61-0P
603270-20-8P 603270-29-7P 603270-73-1P
603270-95-7P 603271-09-6P 603271-17-6P
603271-24-5P 603271-31-4P 603271-47-2P
603271-54-1P 603271-61-0P 603271-67-6P
603271-95-0P 603272-03-3P 603272-09-9P
603272-18-0P 603272-26-0P 603272-35-1P
603272-42-0P 603272-51-1P 603272-60-2P
603272-68-0P 603272-76-0P 603272-82-8P
603272-90-8P 603272-98-6P 603273-06-9P
603273-14-9P 603273-21-8P 603273-28-5P
603273-34-3P 603273-40-1P 603273-49-0P
603273-54-7P 603273-62-7P 603273-69-4P
603273-77-4P 603273-82-1P 603273-91-2P
603273-98-9P 603274-07-3P 603274-14-2P
603274-30-2P 603274-44-8P 603274-60-8P
603274-82-4P 603274-90-4P 603275-05-4P
603275-12-3P 603275-21-4P 603275-30-5P
603275-38-3P 603275-44-1P 603275-53-2P
603275-60-1P 603275-79-2P 603275-86-1P
603275-95-2P 603276-44-4P 603276-75-1P
603276-91-1P 603277-07-2P 603277-22-1P
603277-29-8P 603277-36-7P 603277-44-7P
603277-53-8P 603277-61-8P 603277-67-4P
603277-76-5P 603277-84-5P 603277-92-5P
603277-99-2P 603278-07-5P 603278-14-4P
603278-21-3P 603278-27-9P 603278-34-8P
603278-40-6P 603278-48-4P 603278-55-3P
603278-59-7P 603278-65-5P 603278-71-3P
603278-77-9P 603278-82-6P 603278-89-3P
603278-95-1P 603279-01-2P 603279-09-0P
603279-13-6P 603279-18-1P 603279-23-8P
603279-28-3P 603279-36-3P 603279-44-3P
603279-51-2P 603279-58-9P 603279-64-7P
603279-70-5P 603279-71-6P 603279-77-2P
603279-85-2P 603279-91-0P 603279-97-6P
603280-09-7P 603280-16-6P 603280-24-6P
603280-30-4P 603280-44-0P 603280-50-8P
603280-56-4P 603280-62-2P 603280-73-5P
603280-79-1P 603280-86-0P 603281-00-1P
603281-06-7P 603281-19-2P 603281-25-0P
603281-31-8P 603281-38-5P 603281-53-4P
603281-60-3P 603281-67-0P 603281-90-9P
603281-95-4P 603282-02-6P 603282-21-9P
603282-27-5P 603282-52-6P 603282-75-3P
603282-94-6P 603283-13-2P 603283-31-4P
603283-42-7P 603283-44-9P 603283-50-7P
603283-77-8P 603283-84-7P 603283-91-6P


603283-97-2P 603284-03-3P 603284-08-8P
 603284-13-5P 603284-19-1P 603284-57-7P
 603284-65-7P 603284-70-4P 603284-75-9P
 603285-14-9P 603285-25-2P 603285-39-8P
 603285-56-9P 603285-62-7P 603285-66-1P
 603285-71-8P 603285-77-4P 603285-83-2P
 603285-90-1P 603285-96-7P 603286-09-5P
 603286-28-8P 603286-50-6P 603286-57-3P
 603286-61-9P 603286-68-6P 603286-76-6P
 603286-82-4P 603286-89-1P 603286-95-9P
 603287-03-2P 603287-09-8P 603287-22-5P
 603287-27-0P 603287-32-7P 603287-38-3P
 603287-46-3P 603287-52-1P 603287-58-7P
 603287-64-5P 603287-70-3P 603287-77-0P
 603287-83-8P 603287-88-3P 603287-93-0P
 603288-01-3P 603288-08-0P 603288-16-0P
 603288-22-8P 603288-29-5P 603288-32-0P
 603288-37-5P 603288-43-3P 603288-51-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-(tricyclic fused heteroaryl) 4-heteroaryl substituted 2,5-dioxopyrroles as GSK-3 β kinase inhibitors)

RN 603263-19-0 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-4-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 603263-27-0 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid, 7-[2,5-dihydro-4-[1-(3-hydroxypropyl)-1H-indol-4-yl]-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603263-51-0 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-[2,5-dihydro-4-(4-methoxy-7-benzofuranyl)-2,5-dioxo-1H-pyrrol-3-yl]-3,4-
 dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 603263-74-7 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-[2,5-dihydro-4-(5-methoxy-7-benzofuranyl)-2,5-dioxo-1H-pyrrol-3-yl]-3,4-
 dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603263-99-6 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(5-fluoro-7-benzofuranyl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 603264-20-6 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid, 7-[4-(5-fluoro-7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 603265-10-7 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-[4-(4-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-,
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603265-16-3 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-[4-(1,3-benzodioxol-5-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-
 dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603265-23-2 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603265-28-7 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-(4-benzo[b]thien-4-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl)-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603265-36-7 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-[4-(2,3-dihydro-7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-
 3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603265-45-8 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-[4-(2,3-dihydro-4-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-
 3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 603265-64-1 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-[4-(7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-9-
 methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603265-94-7 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-[2,5-dihydro-4-(6-methoxy-7-benzofuranyl)-2,5-dioxo-1H-pyrrol-3-yl]-3,4-
 dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603266-02-0 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[4-(2,2-difluoro-1,3-benzodioxol-4-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603266-09-7 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-(2,5-dihydro-2,5-dioxo-4-thieno[3,2-b]pyridin-7-yl-1H-pyrrol-3-yl)-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603266-72-4 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 3,4-dihydro-7-[4-(1,3-dihydro-5-isobenzofuranyl)-2,5-dihydro-2,5-dioxo-1H-
 pyrrol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603266-79-1 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-[4-(1H-benzimidazol-4-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-
 dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603266-87-1 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-pyrazolo[1,5-a]pyridin-3-yl-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)




RN 603267-01-2 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid, 7-[4-(7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-9-fluoro-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 603267-08-9 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-[4-(1,3-benzodioxol-4-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-
 dihydro-1-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603267-24-9 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-furo[3,2-c]pyridin-7-yl-4-(1,2,3,4-tetrahydro-1-
 methylpyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, dihydrochloride (9CI)
 (CA INDEX NAME)



● 2 HCl


RN 603267-32-9 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 603267-72-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[1-(3-hydroxypropyl)-1H-indol-4-yl]-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)




RN 603267-87-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(4-methoxy-7-benzofuranyl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 603268-01-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(5-methoxy-7-benzofuranyl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 603268-28-6 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(4-fluoro-7-benzofuranyl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 603268-35-5 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(4,5-difluoro-7-benzofuranyl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)



RN 603268-50-4 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(4-fluoro-5-methoxy-7-benzofuranyl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 603268-64-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyridin-3-yl-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 603268-86-6 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-furo[3,2-c]pyridin-7-yl-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, dihydrochloride
 (9CI) (CA INDEX NAME)




● 2 HCl

RN 603269-09-6 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(4-benzofuranyl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)




RN 603269-15-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1,3-benzodioxol-5-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)




RN 603269-24-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 603269-32-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-benzo[b]thien-7-yl-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)




RN 603269-40-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1,3-benzodioxol-4-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)



RN 603269-45-0 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-benzo[b]thien-4-yl-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)



RN 603269-52-9 CAPLUS


10/506,459

CN 1H-Pyrrole-2,5-dione, 3-(2,3-dihydro-7-benzofuranyl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)




RN 603269-61-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(2,3-dihydro-4-benzofuranyl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)



RN 603270-20-8 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(7-benzofuranyl)-4-(1,2,3,4-tetrahydro-9-methylpyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)



10/506,459


RN 603270-29-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[4-[3-(diethylamino)propoxy]-7-benzofuranyl]-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)



RN 603270-73-1 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(5-isoquinolinyl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 603270-95-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(2,2-difluoro-1,3-benzodioxol-4-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 603271-09-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1,3-dihydro-5-isobenzofuranyl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)



RN 603271-17-6 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(1H-benzimidazol-4-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)



10/506,459

RN 603271-24-5 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(7-benzofuranyl)-4-(1,2,3,4-tetrahydro-3-methylpyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl

RN 603271-31-4 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-3-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 603271-47-2 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 603271-54-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(7-benzofuranyl)-4-(9-fluoro-1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 603271-61-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1,3-benzodioxol-4-yl)-4-(1,2,3,4-tetrahydro-1-methylpyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 603271-67-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyridin-3-yl-4-(1,2,3,4-tetrahydro-1-methylpyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 603271-95-0 CAPLUS

CN Piperidine, 1-[[7-(4-furo[3,2-c]pyridin-7-yl-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-1-yl]carbonyl]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 603272-03-3 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(6-fluoroimidazo[1,2-a]pyridin-3-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 603272-09-9 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(8-aminoimidazo[1,2-a]pyridin-3-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 603272-18-0 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-4-[6-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 603272-26-0 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(8-bromo-6-methylimidazo[1,2-a]pyridin-3-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 603272-35-1 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyrazin-3-yl-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 603272-42-0 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-b]pyridazin-3-yl-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 603272-51-1 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(9-fluoro-1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-4-imidazo[1,2-a]pyridin-3-yl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 603272-60-2 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(6-fluoroimidazo[1,2-a]pyridin-3-yl)-4-(9-fluoro-1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 603272-68-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(8-fluoroimidazo[1,2-a]pyridin-3-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 603272-76-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(7-chloroimidazo[1,2-a]pyridin-3-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 603272-82-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(7-chloroimidazo[1,2-a]pyridin-3-yl)-4-(9-fluoro-1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)



RN 603272-90-8 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(7-chloroimidazo[1,2-a]pyridin-3-yl)-4-(9-fluoro-1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 603272-98-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(8-methoxyimidazo[1,2-a]pyridin-3-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 603273-06-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyridin-3-yl-4-(1,2,3,4-tetrahydro-1-methylpyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 603273-14-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyridin-3-yl-4-(1,2,3,4-tetrahydro-1-methylpyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 603273-21-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(7-chloroimidazo[1,2-a]pyridin-3-yl)-4-(1,2,3,4-tetrahydro-1-methylpyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 603273-28-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(7-chloroimidazo[1,2-a]pyridin-3-yl)-4-(1,2,3,4-tetrahydro-1-methylpyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, (+)- (9CI)
(CA INDEX NAME)


Rotation (+).




RN 603273-34-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(6-methylimidazo[1,2-a]pyridin-3-yl)-4-(1,2,3,4-tetrahydro-1-methylpyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, (-)- (9CI)
(CA INDEX NAME)

Rotation (-).




RN 603273-40-1 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyrimidin-3-yl-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, monohydrochloride
 (9CI) (CA INDEX NAME)



● HCl


RN 603273-49-0 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(6-methoxyimidazo[1,2-a]pyrimidin-3-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, monohydrochloride
 (9CI) (CA INDEX NAME)



● HCl

RN 603273-54-7 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(7-ethylimidazo[1,2-a]pyrimidin-3-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 603273-62-7 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 603273-69-4 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(8-chloroimidazo[1,2-a]pyridin-3-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 603273-77-4 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 2-(3-amino-1-oxopropyl)-7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 603273-82-1 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 2-(2-amino-2-methyl-1-oxopropyl)-7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 603273-91-2 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 2-[(2R)-2-amino-3-methoxy-1-oxopropyl]-7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 603273-98-9 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(9-fluoro-1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-4-(6-methylimidazo[1,2-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 603274-07-3 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(9-fluoro-1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-4-(7-methoxyimidazo[1,2-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 603274-14-2 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(7-methoxyimidazo[1,2-a]pyridin-3-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 603274-30-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(6-chloroimidazo[1,2-a]pyridin-3-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 603274-44-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-7-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 603274-60-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(7-benzofuranyl)-4-(1,2,3,4-tetrahydro-2-methylpyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 603274-82-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyridin-3-yl-4-(1,2,3,4-tetrahydro-2-methylpyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 603274-90-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(5-fluoro-7-benzofuranyl)-4-(1,2,3,4-tetrahydro-2-methylpyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)



RN 603275-05-4 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-furo[3,2-c]pyridin-7-yl-4-(1,2,3,4-tetrahydro-2-methylpyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 603275-12-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-benzo[b]thien-7-yl-4-(1,2,3,4-tetrahydro-2-methylpyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 603275-21-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1,3-benzodioxol-4-yl)-4-(1,2,3,4-tetrahydro-2-methylpyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 603275-30-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(5-fluoro-7-benzofuranyl)-4-[1,2,3,4-tetrahydro-2-(1-methylethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 603275-38-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(2-cyclohexyl-1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-4-(5-fluoro-7-benzofuranyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 603275-44-1 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(7-benzofuranyl)-4-[1,2,3,4-tetrahydro-2-(tetrahydro-2H-pyran-4-yl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 603275-53-2 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(7-benzofuranyl)-4-[1,2,3,4-tetrahydro-2-(1-phenylethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 603275-60-1 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(7-benzofuranyl)-4-[1,2,3,4-tetrahydro-2-(1H-imidazol-2-ylmethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 603275-79-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1,3-benzodioxol-4-yl)-4-[1,2,3,4-tetrahydro-2-(1-methylethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 603275-86-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(2,3-dihydro-7-benzofuranyl)-4-[1,2,3,4-tetrahydro-2-(1-methylethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 603275-95-2 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-(1,2,3,4-tetrahydro-2-methylpyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)



RN 603276-44-4 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(7-benzofuranyl)-4-(2-ethyl-1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 603276-75-1 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(7-benzofuranyl)-4-[1,2,3,4-tetrahydro-2-(1-methylethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 603276-91-1 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(7-benzofuranyl)-4-[1,2,3,4-tetrahydro-2-(tetrahydro-2H-pyran-2-yl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 603277-07-2 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(5-fluoro-7-benzofuranyl)-4-(1,2,3,4-tetrahydro-2-methylpyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 603277-22-1 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(5-fluoro-7-benzofuran-2-yl)-4-[1,2,3,4-tetrahydro-2-(1-methylethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 603277-29-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyridin-3-yl-4-[1,2,3,4-tetrahydro-2-(1-methylethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 603277-36-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-b]pyridazin-3-yl-4-[1,2,3,4-tetrahydro-2-(2-methoxyethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 603277-44-7 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-3-yl)-4-[1,2,3,4-tetrahydro-2-(1-methylethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 603277-53-8 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(2-cyclopentyl-1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-4-imidazo[1,2-a]pyridin-3-yl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 603277-61-8 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[9-fluoro-1,2,3,4-tetrahydro-2-(1-methylethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-4-imidazo[1,2-a]pyridin-3-yl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 603277-67-4 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(6-fluoroimidazo[1,2-a]pyridin-3-yl)-4-[1,2,3,4-tetrahydro-2-(1-methylethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 603277-76-5 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(6-fluoroimidazo[1,2-a]pyridin-3-yl)-4-[9-fluoro-1,2,3,4-tetrahydro-2-(1-methylethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 603277-84-5 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(8-fluoroimidazo[1,2-a]pyridin-3-yl)-4-[9-fluoro-1,2,3,4-tetrahydro-2-(1-methylethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 603277-92-5 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[9-fluoro-1,2,3,4-tetrahydro-2-(1-methylethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-4-imidazo[1,2-a]pyrimidin-3-yl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 603277-99-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(8-fluoroimidazo[1,2-a]pyridin-3-yl)-4-[1,2,3,4-tetrahydro-2-(2-methoxyethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 603278-07-5 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyridin-3-yl-4-[1,2,3,4-tetrahydro-2-(2-methoxyethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 603278-14-4 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyridin-3-yl-4-[1,2,3,4-tetrahydro-2-[2-(2-methoxyethoxy)ethyl]pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI)
 (CA INDEX NAME)




RN 603278-21-3 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyridin-3-yl-4-[1,2,3,4-tetrahydro-2-[2-(4-morpholinyl)ethyl]pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI)
 (CA INDEX NAME)



RN 603278-27-9 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-[(2-fluorophenyl)methyl]-1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-4-imidazo[1,2-a]pyridin-3-yl- (9CI) (CA INDEX NAME)




RN 603278-34-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-[(4-fluorophenyl)methyl]-1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-4-imidazo[1,2-a]pyridin-3-yl- (9CI) (CA INDEX NAME)




RN 603278-40-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-[(2,4-difluorophenyl)methyl]-1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-4-imidazo[1,2-a]pyridin-3-yl- (9CI) (CA INDEX NAME)




RN 603278-48-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyridin-3-yl-4-[1,2,3,4-tetrahydro-2-[(2,4,6-trifluorophenyl)methyl]pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 603278-55-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-[(1-cyclohexyl-1H-imidazol-5-yl)methyl]-1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-4-imidazo[1,2-a]pyridin-3-yl- (9CI) (CA INDEX NAME)




RN 603278-59-7 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(6-methylimidazo[1,2-a]pyridin-3-yl)-4-[1,2,3,4-tetrahydro-2-(2-methoxyethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 603278-65-5 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyridin-3-yl-4-[1,2,3,4-tetrahydro-2-[2-(1-pyrrolidinyl)ethyl]pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI)
 (CA INDEX NAME)




RN 603278-71-3 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(6-methylimidazo[1,2-a]pyridin-3-yl)-4-[1,2,3,4-tetrahydro-2-[2-(4-morpholinyl)ethyl]pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI)
 (CA INDEX NAME)




RN 603278-77-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[9-fluoro-1,2,3,4-tetrahydro-2-[2-(4-morpholinyl)ethyl]pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-4-(6-methylimidazo[1,2-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 603278-82-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[9-fluoro-1,2,3,4-tetrahydro-2-[2-(4-morpholinyl)ethyl]pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-4-(7-methoxyimidazo[1,2-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 603278-89-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(7-methoxyimidazo[1,2-a]pyridin-3-yl)-4-[1,2,3,4-tetrahydro-2-[2-(4-morpholinyl)ethyl]pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 603278-95-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(7-methoxyimidazo[1,2-a]pyridin-3-yl)-4-[1,2,3,4-tetrahydro-2-(2-methoxyethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 603279-01-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(7-chloroimidazo[1,2-a]pyridin-3-yl)-4-[1,2,3,4-tetrahydro-2-(1-methylethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 603279-00-1


CMF C25 H22 Cl N5 O2



CM 2

CRN 75-75-2

CMF C H4 O3 S



10/506,459


RN 603279-09-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(8-fluoroimidazo[1,2-a]pyridin-3-yl)-4-[1,2,3,4-tetrahydro-2-(1-methylethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 603279-08-9


CMF C25 H22 F N5 O2



CM 2


CRN 75-75-2

CMF C H4 O3 S




RN 603279-13-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(8-methoxyimidazo[1,2-a]pyridin-3-yl)-4-[1,2,3,4-tetrahydro-2-(2-methoxyethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 603279-18-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(7-chloroimidazo[1,2-a]pyridin-3-yl)-4-[9-fluoro-1,2,3,4-tetrahydro-2-(2-methoxyethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 603279-23-8 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyridin-3-yl-4-[1,2,3,4-tetrahydro-2-(tetrahydro-2H-pyran-4-yl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 603279-28-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyridin-3-yl-4-[1,2,3,4-tetrahydro-1-methyl-2-(1-methylethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-, (-)-(9CI) (CA INDEX NAME)


Rotation (-).



RN 603279-36-3 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyridin-3-yl-4-[1,2,3,4-tetrahydro-1-methyl-2-(1-methylethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).




RN 603279-44-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(7-chloroimidazo[1,2-a]pyridin-3-yl)-4-[1,2,3,4-tetrahydro-2-(2-methoxyethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 603279-51-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-pyrrolo[2,1-b]thiazol-3-yl-4-[1,2,3,4-tetrahydro-2-(1-methylethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 603279-58-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(6-methoxyimidazo[1,2-a]pyridin-3-yl)-4-[1,2,3,4-tetrahydro-2-(2-methoxyethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-(9CI) (CA INDEX NAME)




RN 603279-64-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(7-ethylimidazo[1,2-a]pyridin-3-yl)-4-[1,2,3,4-tetrahydro-2-(2-methoxyethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-(9CI) (CA INDEX NAME)



RN 603279-70-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyrimidin-3-yl-4-[1,2,3,4-tetrahydro-2-(1-methylethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 603279-71-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyrimidin-3-yl-4-[1,2,3,4-tetrahydro-2-(1-methylethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 603279-70-5


CMF C24 H22 N6 O2



CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 603279-77-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(2-cyclopentyl-1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-4-imidazo[1,2-a]pyrimidin-3-yl- (9CI) (CA INDEX NAME)




RN 603279-85-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(6-chloroimidazo[1,2-a]pyridin-3-yl)-4-[1,2,3,4-tetrahydro-2-(1-methylethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-


10/506,459

(9CI) (CA INDEX NAME)




RN 603279-91-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-[(2-fluorophenyl)methyl]-1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-4-imidazo[1,2-a]pyrimidin-3-yl- (9CI) (CA INDEX NAME)




RN 603279-97-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyrimidin-3-yl-4-[1,2,3,4-tetrahydro-2-(3-pyridinylmethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 603280-09-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-pyrazolo[1,5-a]pyrimidin-3-yl-4-[1,2,3,4-tetrahydro-2-(1-methylethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




i-Pr

● HCl

RN 603280-16-6 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-pyrazolo[1,5-a]pyrimidin-3-yl-4-(1,2,3,4-tetrahydro-2-methylpyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 603280-24-6 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(1,2,3,4-tetrahydro-2-methylpyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 603280-30-4 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[1,2,3,4-tetrahydro-2-(1-methylethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 603280-44-0 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxaldehyde,
7-[4-(7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-
(9CI) (CA INDEX NAME)




RN 603280-50-8 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[4-(7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-,
phenyl ester (9CI) (CA INDEX NAME)




RN 603280-56-4 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-[4-(7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-,
 3-(trifluoromethyl)phenyl ester (9CI) (CA INDEX NAME)




RN 603280-62-2 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-[4-(7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-,
 4-methoxyphenyl ester (9CI) (CA INDEX NAME)




RN 603280-73-5 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-[4-(1,3-benzodioxol-4-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-
 dihydro-, methyl ester (9CI) (CA INDEX NAME)




RN 603280-79-1 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-[4-(7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-,
 ethyl ester (9CI) (CA INDEX NAME)




RN 603280-86-0 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-[4-(7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-,
 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 603281-00-1 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-[4-(7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-,
 butyl ester (9CI) (CA INDEX NAME)



RN 603281-06-7 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-[4-(7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-,
 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 603281-19-2 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(1,3-benzodioxol-4-yl)-2,5-
 dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-[(4-methyl-1-
 piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 603281-25-0 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603281-31-8 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603281-38-5 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(7-cyanoimidazo[1,2-a]pyridin-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603281-53-4 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603281-60-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603281-67-0 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-2-(2,2-dimethyl-1-oxopropyl)-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 603281-90-9 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
 7-[4-(7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-
 N,N-dimethyl- (CA INDEX NAME)




RN 603281-95-4 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
 7-[4-(5-fluoro-7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-
 dihydro-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 603282-02-6 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
 dihydro-N,N-dimethyl- (CA INDEX NAME)




RN 603282-21-9 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
 7-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-
 yl)-3,4-dihydro-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 603282-27-5 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
 7-[4-(1,3-benzodioxol-4-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-
 dihydro-N,N-dimethyl- (CA INDEX NAME)




RN 603282-52-6 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
 7-[4-(1,3-benzodioxol-4-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-
 dihydro-N,N,1-trimethyl- (9CI) (CA INDEX NAME)



RN 603282-75-3 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
 dihydro-N,N,1-trimethyl- (9CI) (CA INDEX NAME)




RN 603282-94-6 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-
 a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(1-
 oxopropyl)- (9CI) (CA INDEX NAME)




RN 603283-13-2 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 603283-31-4 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 2-acetyl-7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 603283-42-7 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 2-acetyl-7-[4-(5-fluoro-7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-
 (9CI) (CA INDEX NAME)




RN 603283-44-9 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2-(1-oxobutyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(1-oxobutyl)-
 (9CI) (CA INDEX NAME)




RN 603283-50-7 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 603283-77-8 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(4-furo[3,2-c]pyridin-7-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(1-oxopropyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 603283-84-7 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 2-acetyl-7-(4-furo[3,2-c]pyridin-7-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 603283-91-6 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(2-acetyl-1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-4-(1,3-benzodioxol-4-yl)- (CA INDEX NAME)




RN 603283-97-2 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 2-acetyl-7-(4-benzo[b]thien-7-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 603284-03-3 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(1,3-benzodioxol-4-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 603284-08-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(2-acetyl-1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-4-(2,3-dihydro-7-benzofuranyl)- (CA INDEX NAME)




RN 603284-13-5 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(2,3-dihydro-7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 603284-19-1 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(2,3-dihydro-7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(1-oxobutyl)-(9CI) (CA INDEX NAME)




RN 603284-57-7 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide, 7-(4-furo[3,2-c]pyridin-7-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl)-3,4-dihydro-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 603284-65-7 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(4-furo[3,2-c]pyridin-7-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 603284-70-4 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(4-furo[3,2-c]pyridin-7-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-[(4-methyl-1-piperazinyl)carbonyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 603284-75-9 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(4-furo[3,2-c]pyridin-7-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(1-pyrrolidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 603285-14-9 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(4-furo[3,2-c]pyridin-7-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)




RN 603285-25-2 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(4-furo[3,2-c]pyridin-7-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(1-oxooctyl)-, monohydrochloride (9CI) (CA INDEX NAME)




RN 603285-39-8 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(4-furo[3,2-c]pyridin-7-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-1-methyl-2-(4-morpholinylcarbonyl)-, dihydrochloride (9CI) (CA INDEX NAME)



RN 603285-56-9 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
 dihydro-, ethyl ester (9CI) (CA INDEX NAME)




RN 603285-62-7 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
 dihydro-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 603285-66-1 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(1-oxobutyl)- (9CI) (CA INDEX NAME)




RN 603285-71-8 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 603285-77-4 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(5-fluoro-7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(1-oxopropyl)-(9CI) (CA INDEX NAME)




RN 603285-83-2 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(5-fluoro-7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(1-oxobutyl)-(9CI) (CA INDEX NAME)




RN 603285-90-1 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(5-fluoro-7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 603285-96-7 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide, 7-[4-(5-fluoro-7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-N-methyl- (9CI) (CA INDEX NAME)




RN 603286-09-5 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(5-fluoro-7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603286-28-8 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide, 7-[4-(7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-N-methyl- (9CI) (CA INDEX NAME)




RN 603286-50-6 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-3-methyl-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603286-57-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-4-methyl-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603286-61-9 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(1-oxooctyl)-(9CI) (CA INDEX NAME)




RN 603286-68-6 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-4,4-dimethyl-2-(4-morpholinylcarbonyl)-(9CI) (CA INDEX NAME)




RN 603286-76-6 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-10-fluoro-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603286-82-4 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide, 7-[4-(6-fluoroimidazo[1,2-a]pyridin-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 603286-89-1 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(6-fluoroimidazo[1,2-a]pyridin-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 603286-95-9 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(8-cyanoimidazo[1,2-a]pyridin-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603287-03-2 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(8-cyanoimidazo[1,2-a]pyridin-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603287-09-8 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(8-aminoimidazo[1,2-a]pyridin-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603287-22-5 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(6,8-dimethylimidazo[1,2-a]pyridin-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603287-27-0 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(8-bromo-6-methylimidazo[1,2-a]pyridin-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603287-32-7 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyrazin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603287-38-3 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyrazin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603287-46-3 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-b]pyridazin-3-yl-4-[1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (CA INDEX NAME)




RN 603287-52-1 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid, 7-(2,5-dihydro-4-imidazo[1,2-b]pyridazin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-3,4-dihydro-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 603287-58-7 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[2,5-dihydro-4-(6-methylimidazo[1,2-b]pyridazin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603287-64-5 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid, 7-[2,5-dihydro-4-(6-methylimidazo[1,2-b]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 603287-70-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[2,5-dihydro-4-(7-methylimidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-
3-yl]-3,4-dihydro-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 603287-77-0 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[2,5-dihydro-4-(8-methylimidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-
3-yl]-3,4-dihydro-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 603287-83-8 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[2,5-dihydro-4-(2-methylimidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603287-88-3 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[2,5-dihydro-4-(6-methylimidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 603287-93-0 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[2,5-dihydro-4-(6-methylimidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-9-fluoro-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603288-01-3 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[2,5-dihydro-4-(5-methylimidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603288-08-0 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[2,5-dihydro-4-(8-methylimidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-9-fluoro-3,4-dihydro-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 603288-16-0 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[4-(8-fluoroimidazo[1,2-a]pyridin-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 603288-22-8 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-9-fluoro-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603288-29-5 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(6-fluoroimidazo[1,2-a]pyridin-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603288-32-0 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(8-fluoroimidazo[1,2-a]pyridin-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603288-37-5 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[2,5-dihydro-4-(6-methylimidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(1-oxobutyl)- (9CI) (CA INDEX NAME)




RN 603288-43-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[2,5-dihydro-4-(7-methoxyimidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(1-oxobutyl)- (9CI) (CA INDEX NAME)



RN 603288-51-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid, 7-[2,5-dihydro-4-(7-methoxyimidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-, 1-methylethyl ester (9CI) (CA INDEX NAME)



IT	603288-58-0P	603288-65-9P	603288-71-7P
	603288-76-2P	603288-81-9P	603288-89-7P
	603288-96-6P	603289-03-8P	603289-09-4P
	603289-16-3P	603289-23-2P	603289-30-1P
	603289-36-7P	603289-42-5P	603289-44-7P
	603289-51-6P	603289-58-3P	603289-63-0P
	603289-74-3P	603289-80-1P	603289-86-7P
	603289-92-5P	603289-97-0P	603290-03-5P
	603290-10-4P	603290-24-0P	603290-30-8P
	603290-36-4P	603290-43-3P	603290-48-8P
	603290-55-7P	603290-62-6P	603290-68-2P
	603290-74-0P	603290-80-8P	603290-85-3P
	603290-92-2P	603290-98-8P	603291-04-9P
	603291-10-7P	603291-16-3P	603291-23-2P
	603291-29-8P	603291-36-7P	603291-43-6P
	603291-51-6P	603291-57-2P	603291-62-9P
	603291-69-6P	603291-77-6P	603291-82-3P
	603291-87-8P	603291-94-7P	603291-99-2P
	603292-05-3P	603292-11-1P	603292-16-6P
	603292-20-2P	603292-24-6P	603292-32-6P
	603292-37-1P	603292-44-0P	603292-51-9P
	603292-56-4P	603292-62-2P	603292-68-8P
	603292-72-4P	603292-78-0P	603292-83-7P
	603292-89-3P	603292-95-1P	603293-01-2P
	603293-07-8P	603293-13-6P	603293-85-2P
	603293-95-4P	603294-00-4P	603294-06-0P
	603294-12-8P	603294-39-9P	603294-43-5P
	603294-49-1P	603294-55-9P	603294-61-7P
	603294-69-5P	603294-76-4P	603294-81-1P
	603294-87-7P	603294-93-5P	603294-99-1P
	603295-04-1P	603295-09-6P	603295-14-3P
	603295-18-7P	603295-24-5P	603295-30-3P
	603295-35-8P	603295-41-6P	603295-47-2P
	603295-53-0P	603295-59-6P	603295-65-4P
	603295-71-2P	603295-76-7P	603295-82-5P
	603295-88-1P	603295-93-8P	603295-98-3P
	603296-03-3P	603296-10-2P	603296-17-9P
	603296-22-6P	603296-27-1P	603296-30-6P
	603296-33-9P	603296-39-5P	603296-45-3P


603296-57-7P 603296-60-2P 603296-65-7P
 603296-72-6P 603296-78-2P 603296-91-9P
 603296-97-5P 603297-08-1P 603297-13-8P
 603297-18-3P 603297-22-9P 603297-35-4P
 603297-52-5P 603297-63-8P 603297-69-4P
 603297-74-1P 603297-89-8P 603297-95-6P
 603298-09-5P 603298-15-3P 603298-21-1P
 603298-28-8P 603298-33-5P 603298-39-1P
 603298-44-8P 603298-50-6P 603298-58-4P
 603298-77-7P 603298-83-5P 603299-04-3P
 603299-11-2P 603299-19-0P 603299-35-0P
 603299-40-7P 603299-46-3P 603299-49-6P
 603299-55-4P 603299-61-2P 603299-66-7P
 603299-73-6P 603299-77-0P 603299-83-8P
 603299-89-4P 603300-09-0P 603300-15-8P
 603300-20-5P 603300-25-0P 603300-30-7P
 603300-36-3P 603300-42-1P 603300-48-7P
 603300-53-4P 603300-58-9P 603300-63-6P
 603300-66-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of 3-(tricyclic fused heteroaryl) 4-heteroaryl substituted
 2,5-dioxopyrroles as GSK-3 β kinase inhibitors)


RN 603288-58-0 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[2,5-dihydro-4-(7-
 methoxyimidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-
 tetrahydro-2-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603288-65-9 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(8-fluoroimidazo[1,2-a]pyridin-
 3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(4-
 morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603288-71-7 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[2,5-dihydro-4-(8-methoxyimidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603288-76-2 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[2,5-dihydro-2,5-dioxo-4-[8-(phenylmethoxy)imidazo[1,2-a]pyridin-3-yl]-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603288-81-9 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(7-chloroimidazo[1,2-a]pyridin-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603288-89-7 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[2,5-dihydro-4-(8-methoxyimidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603288-96-6 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[2,5-dihydro-4-(8-methoxyimidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-
3-yl]-3,4-dihydro-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 603289-03-8 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(7-chloroimidazo[1,2-a]pyridin-
3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(1-
piperidinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 603289-09-4 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-1-methyl-2-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 603289-16-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-1-methyl-2-(2-methyl-1-oxopropyl)-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 603289-23-2 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-1-methyl-2-(2-methyl-1-oxopropyl)-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 603289-30-1 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-3,4-dihydro-N,N,1-trimethyl-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 603289-36-7 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
dihydro-N,N,1-trimethyl-, monohydrochloride, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




● HCl

RN 603289-42-5 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
dihydro-N,N,1-trimethyl-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 603289-44-7 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
dihydro-N,N,1-trimethyl-, monohydrochloride, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



● HCl

RN 603289-51-6 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-
a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-1-methyl-2-(4-
morpholinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 603289-58-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-1-methyl-2-(4-morpholinylcarbonyl)-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 603289-63-0 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-1-methyl-2-(4-morpholinylcarbonyl)-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 603289-74-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(7-chloroimidazo[1,2-a]pyridin-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-1-methyl-2-(1-piperidinyldicarbonyl)-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).




RN 603289-80-1 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[2,5-dihydro-4-(6-methylimidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-1-methyl-2-(1-piperidinyldicarbonyl)-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 603289-86-7 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-[4-(7-chloroimidazo[1,2-a]pyridin-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-
 3-yl]-3,4-dihydro-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 603289-92-5 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 2-(cyclopropylcarbonyl)-7-(2,5-
 dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-
 tetrahydro- (9CI) (CA INDEX NAME)




RN 603289-97-0 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[2,1-b]thiazol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 603290-03-5 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[2,1-b]thiazol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603290-10-4 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-2,5-dioxo-4-thiazolo[3,2-b][1,2,4]triazol-2-yl-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A






RN 603290-24-0 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
 dihydro-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 603290-30-8 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
 dihydro-, propyl ester (9CI) (CA INDEX NAME)




RN 603290-36-4 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
dihydro-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)



RN 603290-43-3 CAPLUS
CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
dihydro-, 2-fluoroethyl ester (9CI) (CA INDEX NAME)




RN 603290-48-8 CAPLUS
CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
dihydro-, phenyl ester (9CI) (CA INDEX NAME)




RN 603290-55-7 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[2,5-dihydro-4-(6-methoxyimidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 603290-62-6 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[2,5-dihydro-4-(6-methoxyimidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603290-68-2 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[4-(6-chloroimidazo[1,2-a]pyridin-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 603290-74-0 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(6-chloroimidazo[1,2-a]pyridin-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(1-piperidinyl)carboxyl)- (9CI) (CA INDEX NAME)




RN 603290-80-8 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(6-bromoimidazo[1,2-a]pyridin-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603290-85-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid, 7-[4-(7-ethylimidazo[1,2-a]pyridin-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 603290-92-2 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[2,5-dihydro-4-(imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-
3,4-dihydro-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 603290-98-8 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[2,5-dihydro-4-[6-(1-
methylethyl)imidazo[1,2-a]pyridin-3-yl]-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-
tetrahydro-2-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603291-04-9 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[2,5-dihydro-4-[6-(1-methylethyl)imidazo[1,2-a]pyridin-3-yl]-2,5-dioxo-
1H-pyrrol-3-yl]-3,4-dihydro-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 603291-10-7 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-
a]pyrimidin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(4-
morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603291-16-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyrimidin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603291-23-2 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid, 7-(2,5-dihydro-4-imidazo[1,2-a]pyrimidin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-3,4-dihydro-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 603291-29-8 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(7-aminoimidazo[1,2-a]pyrimidin-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603291-36-7 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-c]pyrimidin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603291-43-6 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(7-aminoimidazo[1,2-c]pyrimidin-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603291-51-6 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(6-ethylimidazo[1,2-a]pyrimidin-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603291-57-2 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
7-[2,5-dihydro-2,5-dioxo-4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)-
1H-pyrrol-3-yl]-3,4-dihydro-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 603291-62-9 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
7-(2,5-dihydro-2,5-dioxo-4-pyrazolo[1,5-a]pyridin-3-yl-1H-pyrrol-3-yl)-3,4-
dihydro-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 603291-69-6 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
N,N-dibutyl-7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-
pyrrol-3-yl)-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 603291-77-6 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-2,5-dioxo-4-
pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(2-methyl-
1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 603291-82-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
7-(2,5-dihydro-2,5-dioxo-4-pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrrol-3-yl)-3,4-
dihydro-N,N-dimethyl- (CA INDEX NAME)




RN 603291-87-8 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[2,5-dihydro-2,5-dioxo-4-(4,5,6,7-
tetrahydropyrazolo[1,5-a]pyridin-3-yl)-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-
2-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 603291-94-7 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
7-[2,5-dihydro-2,5-dioxo-4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)-
1H-pyrrol-3-yl]-3,4-dihydro-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 603291-99-2 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[2,5-dihydro-2,5-dioxo-4-(4,5,6,7-
tetrahydropyrazolo[1,5-a]pyridin-3-yl)-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-
2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603292-05-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
dihydro-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 603292-11-1 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-2,5-dioxo-4-
pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(4-
morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603292-16-6 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[2,5-dihydro-2,5-dioxo-4-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-3-yl)-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603292-20-2 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide, 7-[2,5-dihydro-2,5-dioxo-4-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-3-yl)-1H-pyrrol-3-yl]-3,4-dihydro-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 603292-24-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(9-chloro-1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-4-imidazo[1,2-a]pyridin-3-yl- (9CI) (CA INDEX NAME)




RN 603292-32-6 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 9-chloro-7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603292-37-1 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
 9-chloro-7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-3,4-dihydro-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 603292-44-0 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-N,N-diethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 603292-51-9 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-[(4-phenyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 603292-56-4 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-2-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]carbonyl]-1,2,3,4-tetrahydro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 603292-62-2 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-2-[(4,4-dimethyl-1-piperidinyl)carbonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 603292-68-8 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(1H-imidazol-1-ylcarbonyl)- (9CI) (CA INDEX NAME)



RN 603292-72-4 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[2,5-dihydro-2,5-dioxo-4-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-3-yl)-1H-pyrrol-3-yl]-2-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]carbonyl]-1,2,3,4-tetrahydro-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 603292-78-0 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-2,5-dioxo-4-pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrrol-3-yl)-2-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]carbonyl]-1,2,3,4-tetrahydro-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 603292-83-7 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[2,5-dihydro-2,5-dioxo-4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)-1H-pyrrol-3-yl]-2-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]carbonyl]-1,2,3,4-tetrahydro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 603292-89-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 603292-95-1 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 9-chloro-7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603293-01-2 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(8-chloroimidazo[1,2-a]pyridin-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 603293-07-8 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(8-chloroimidazo[1,2-a]pyridin-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603293-13-6 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid, 7-[4-(8-chloroimidazo[1,2-a]pyridin-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 603293-85-2 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 603293-95-4 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-[(2-methoxyethoxy)acetyl]- (9CI) (CA INDEX NAME)




RN 603294-00-4 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-2-[(dimethylamino)acetyl]-1,2,3,4-tetrahydro-
(9CI) (CA INDEX NAME)




RN 603294-06-0 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(3-pyridinylcarbonyl)-
(9CI) (CA INDEX NAME)




RN 603294-12-8 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(pyrazinylcarbonyl)- (9CI)
(CA INDEX NAME)




RN 603294-39-9 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(4-furo[3,2-c]pyridin-7-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(oxoacetyl)- (9CI)
(CA INDEX NAME)



RN 603294-43-5 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[2,5-dihydro-4-(6-methylimidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(3-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603294-49-1 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-9-fluoro-1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)-1-oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 603294-55-9 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 2-(difluoroacetyl)-7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-(9CI) (CA INDEX NAME)




RN 603294-61-7 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(8-fluoroimidazo[1,2-a]pyridin-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 603294-69-5 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[2,5-dihydro-2,5-dioxo-4-[8-(phenylmethoxy)imidazo[1,2-a]pyridin-3-yl]-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 603294-76-4 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-[(tetrahydro-2H-pyran-4-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 603294-81-1 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(3-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603294-87-7 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-[(6-methyl-3-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 603294-93-5 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(6-chloroimidazo[1,2-a]pyridin-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(2-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603294-99-1 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-[(1-oxido-3-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 603295-04-1 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-[[2-(trifluoromethyl)-4-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 603295-09-6 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-[[6-[2-(1-pyrrolidinyl)ethyl]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 603295-14-3 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[[7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-3,4-dihydropyrrolo[3,2,1-jk][1,4]benzodiazepin-2(1H)-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 603295-18-7 CAPLUS

CN 4-Pyridinecarboxylic acid, 2-[[7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydropyrrolo[3,2,1-jk][1,4]benzodiazepin-2(1H)-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 603295-24-5 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(pyrazinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603295-30-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(2-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 603295-35-8 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(5-pyrimidinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 603295-41-6 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-[(2R)-1-methyl-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 603295-47-2 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-[3-(1H-imidazol-4-yl)-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 603295-53-0 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-[(1-methyl-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 603295-59-6 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-[3-(4-morpholinyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 603295-65-4 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(1H-imidazol-4-ylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603295-71-2 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-2-[(1,1-dioxido-4-thiomorpholinyl)acetyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)


PAGE 1-A





RN 603295-76-7 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(1H-imidazol-2-ylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603295-82-5 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-[3-(4-nitro-1H-imidazol-1-yl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 603295-88-1 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-2-[(6,7-dihydro-3-methyl-5H-pyrrolo[1,2-a]imidazol-6-yl)carbonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 603295-93-8 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-[4-(4-nitro-1H-imidazol-1-yl)-1-oxobutyl]- (9CI) (CA INDEX NAME)



RN 603295-98-3 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 2-(3-azetidinyldicarbonyl)-7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 603296-03-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
dihydro-, 2-(4-morpholinyl)ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 603296-10-2 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
 dihydro-, 2-(1-pyrrolidinyl)ethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 603296-17-9 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-
 a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(1-
 piperazinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603296-22-6 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
dihydro-N,N-bis(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 603296-27-1 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
dihydro-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 603296-30-6 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-[(tetrahydro-1,4-oxazepin-4(5H)-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 603296-33-9 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-3,4-dihydro-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 603296-39-5 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-[(4-oxo-1-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 603296-45-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-sulfonamide, 7-[4-(7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 603296-57-7 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-sulfonamide,
 7-(4-furo[3,2-c]pyridin-7-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
 dihydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 603296-60-2 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-sulfonamide,
 7-[4-(5-fluoro-7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-
 dihydro- (9CI) (CA INDEX NAME)




RN 603296-65-7 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-sulfonamide,
7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
dihydro- (9CI) (CA INDEX NAME)




RN 603296-72-6 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-
a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-[(1-methyl-
1H-imidazol-4-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 603296-78-2 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-sulfonamide,
7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
dihydro-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 603296-91-9 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
7-[4-(7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-
(9CI) (CA INDEX NAME)




RN 603296-97-5 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
7-[4-(1,3-benzodioxol-4-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-
dihydro-N-methyl- (9CI) (CA INDEX NAME)




RN 603297-08-1 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
7-[4-(2,3-dihydro-7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-
3,4-dihydro- (9CI) (CA INDEX NAME)




RN 603297-13-8 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
7-[4-(1,3-benzodioxol-4-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-
dihydro- (9CI) (CA INDEX NAME)




RN 603297-18-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
7-(4-furo[3,2-c]pyridin-7-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
dihydro-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 603297-22-9 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
 dihydro-N-methyl- (9CI) (CA INDEX NAME)




RN 603297-35-4 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxamide,
 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
 dihydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 603297-52-5 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(1-piperidinylacetyl)- (9CI) (CA INDEX NAME)




RN 603297-63-8 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-acetonitrile, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 603297-69-4 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-acetic acid,
7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 603297-74-1 CAPLUS

CN Morpholine, 4-[[7-[4-(7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydropyrrolo[3,2,1-jk][1,4]benzodiazepin-2(1H)-yl]acetyl]- (9CI)
(CA INDEX NAME)




RN 603297-89-8 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-acetamide, 7-[4-(5-fluoro-7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro- (9CI)
(CA INDEX NAME)




RN 603297-95-6 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-acetic acid, 7-[4-(5-fluoro-7-benzofuranyl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 603298-09-5 CAPLUS

CN Morpholine, 4-[[7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-3,4-dihydropyrrolo[3,2,1-jk][1,4]benzodiazepin-2(1H)-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 603298-15-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyridin-3-yl-4-[1,2,3,4-tetrahydro-2-(3-pyridinylmethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 603298-14-2


CMF C28 H22 N6 O2



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 603298-21-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyridin-3-yl-4-[1,2,3,4-tetrahydro-2-(4-pyridinylmethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 603298-20-0


CMF C28 H22 N6 O2



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 603298-28-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(6-fluoroimidazo[1,2-a]pyridin-3-yl)-4-[1,2,3,4-tetrahydro-2-(2-pyridinylmethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 603298-27-7


CMF C28 H21 F N6 O2



CM 2


CRN 75-75-2

CMF C H4 O3 S




RN 603298-33-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(6-methylimidazo[1,2-a]pyridin-3-yl)-4-[1,2,3,4-tetrahydro-2-(2-pyridinylmethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-(9CI) (CA INDEX NAME)



RN 603298-39-1 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-acetic acid,
7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
dihydro-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 603298-44-8 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-acetic acid,
7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
dihydro-, 1-methylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 603298-50-6 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-acetamide, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-N,N-diethyl-3,4-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 603298-58-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyridin-3-yl-4-[1,2,3,4-tetrahydro-2-(2,2,3,3,3-pentafluoropropyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-(9CI) (CA INDEX NAME)




RN 603298-77-7 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(4-hydroxy-7-benzofuranyl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 603298-83-5 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(5-hydroxy-7-benzofuranyl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, monohydrochloride. (9CI) (CA INDEX NAME)



● HCl


RN 603299-04-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[4-[4-[3-(diethylamino)propoxy]-7-benzofuranyl]-2,5-dihydro-2,5-dioxo-1H-
pyrrol-3-yl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603299-11-2 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-[4-(7-benzofuranyl)-2,5-dihydro-
2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-(4-morpholinylacetyl)-,
monohydrochloride (9CI) (CA INDEX NAME)




RN 603299-19-0 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 2-[(cyanoimino)-4-morpholinylmethyl]-
7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-
1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 603299-35-0 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 2-[(cyanoimino)-1-piperidinylmethyl]-
7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-
1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 603299-40-7 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboximidamide,
 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
 dihydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 603299-46-3 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-
 a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(1-
 iminoethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 603299-49-6 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboximidamide,
 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
 dihydro-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 603299-55-4 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-(5-amino-1H-1,2,4-triazol-3-yl)-1,2,3,4-
 tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-4-imidazo[1,2-
 a]pyridin-3-yl- (9CI) (CA INDEX NAME)




RN 603299-61-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyridin-3-yl-4-[1,2,3,4-tetrahydro-2-(2-pyridinyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 603299-66-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(6-methylimidazo[1,2-a]pyridin-3-yl)-4-[1,2,3,4-tetrahydro-2-(2-pyridinyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 603299-73-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyridin-3-yl-4-[1,2,3,4-tetrahydro-2-(2-pyrimidinyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 603299-77-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-(2-benzothiazolyl)-1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-4-imidazo[1,2-a]pyridin-3-yl- (9CI) (CA INDEX NAME)




RN 603299-83-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(7-chloroimidazo[1,2-a]pyridin-3-yl)-4-[9-fluoro-1,2,3,4-tetrahydro-2-(2-pyrimidinyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 603299-89-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(6-methylimidazo[1,2-a]pyridin-3-yl)-4-[1,2,3,4-tetrahydro-2-(2-pyrimidinyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 603300-09-0 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carbothioic acid,
7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
dihydro-, O-methyl ester (9CI) (CA INDEX NAME)




RN 603300-15-8 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-
a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(4-
morpholinylthiomethyl)- (9CI) (CA INDEX NAME)




RN 603300-20-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(7-benzofuranyl)-4-[1,2,3,4-tetrahydro-2-(4-pyridinyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 603300-25-0 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyridin-3-yl-4-(1,2,3,4-tetrahydro-2-methyl-1-oxopyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 603300-30-7 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(4-morpholinylacetyl)- (9CI) (CA INDEX NAME)




RN 603300-36-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(4-thiomorpholinylacetyl)- (9CI) (CA INDEX NAME)



RN 603300-42-1 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(4-thiazolidinylcarbonyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 603300-48-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyridin-3-yl-4-[1,2,3,4-tetrahydro-2-(3,3,3-trifluoropropyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 603300-53-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(6-methylimidazo[1,2-a]pyridin-3-yl)-4-[1,2,3,4-tetrahydro-2-(3,3,3-trifluoropropyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 603300-58-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyridin-3-yl-4-[1,2,3,4-tetrahydro-2-[(1-methyl-1H-imidazol-5-yl)methyl]pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 603300-63-6 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyridin-3-yl-4-[1,2,3,4-tetrahydro-2-[2-(1-piperidinyl)ethyl]pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI)
(CA INDEX NAME)




RN 603300-66-9 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid, 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-3,4-dihydro-, 2-(1-piperidinyl)ethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




IT 603312-04-5 603312-95-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 3-(tricyclic fused heteroaryl) 4-heteroaryl substituted
 2,5-dioxopyrroles as GSK-3 β kinase inhibitors)
 RN 603312-04-5 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-[2,5-dihydro-4-(1H-indol-7-yl)-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-,
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 603312-95-4 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboximidic acid,
N-cyano-7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-3,4-dihydro-, phenyl ester (9CI) (CA INDEX NAME)




IT 603307-42-2P 603307-47-7P 603307-58-0P
603307-64-8P 603307-69-3P 603307-74-0P
603307-80-8P 603307-85-3P 603307-92-2P
603310-08-3P 603312-89-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of 3-(tricyclic fused heteroaryl) 4-heteroaryl substituted
2,5-dioxopyrroles as GSK-3 β kinase inhibitors)


RN 603307-42-2 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-(4-furo[3,2-c]pyridin-7-yl-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl)-3,4-
dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603307-47-7 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[2,5-dihydro-4-(5-isoquinolinyl)-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603307-58-0 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-[(2,4-dimethoxyphenyl)methyl]-1,2,3,4-
tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-4-imidazo[1,2-
a]pyridin-3-yl- (9CI) (CA INDEX NAME)



RN 603307-64-8 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl)-10-
 fluoro-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603307-69-3 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-[4-(7-chloroimidazo[1,2-a]pyridin-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-
 3-yl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603307-74-0 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[4-(7-chloroimidazo[1,2-a]pyridin-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-9-fluoro-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603307-80-8 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[2,5-dihydro-4-(8-methoxyimidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603307-85-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[4-(6-chloroimidazo[1,2-a]pyridin-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603307-92-2 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-(2,5-dihydro-4-imidazo[1,2-a]pyrimidin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-
3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 603310-08-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyridin-3-yl-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (CA INDEX NAME)



RN 603312-89-6 CAPLUS

CN Carbamic acid, [[7-(2,5-dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-3,4-dihydropyrrolo[3,2,1-jk][1,4]benzodiazepin-2(1H)-yl][[(1,1-dimethylethoxy)carbonyl]amino]methylene]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:453066 CAPLUS

DOCUMENT NUMBER: 135:61239

TITLE: Preparation of 11H,12H,14H-pyrrolo[3,4-c]quinolino[8',8a',1':3,2,1]-pyrrolo[2,3-a]carbazole-5,7-diones for the treatment of proliferative diseases

INVENTOR(S): Al-Awar, Rima Salim; Hecker, Kyle Andrew; Huang, Jianping; Joseph, Sajjan; Li, Tiechao; Paal, Michael; Rathnachalam, Radhakrishnan; Ray, James Edward; Shih, Chuan; Waid, Philip Parker; Zhou, Xun; Zhu, Guoxin

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 261 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001044247	A2	20010621	WO 2000-US33273	20001218
WO 2001044247	A3	20020103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001020722	A5	20010625	AU 2001-20722	20001218
EP 1242420	A2	20020925	EP 2000-984043	20001218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003229026	A1	20031211	US 2002-130493	20021202
US 6867198	B2	20050315		
PRIORITY APPLN. INFO.:			US 1999-171087P	P 19991216
			US 1999-171220P	P 19991216
			WO 2000-US33273	W 20001218
OTHER SOURCE(S):			MARPAT 135:61239	
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; A, B = O, S; X, Y = H; or X and Y, taken together, form a bond; R1 = H, alkyl; R2 = halo, CN, alkyl, etc.; R3 = aryl, heteroaryl, etc.; R4 = H, alkyl, etc.; R5 = halo, CN, alkyl, etc.; R6 = alkyl; R7 = alkoxycarbonyl, (CH₂)_mZ (m = 0-5; Z = halo, OH, etc.); Q1 = O, SOn (n = 0-2), (CH₂)₁₋₃; Q2 = carbon-carbon single or double bond, etc.; Q3 = (CH₂)₁₋₃], useful for inhibiting CDK4, were prepared and formulated. E.g., a multi-step synthesis of II which showed activity (0.1055 μ M) in assay of cyclin D1-CDK4 kinase with the ING peptide as substrate, and also was found to inhibit cell growth and Rb (retinoblastoma protein) phosphorylation, was given..

IT 345262-54-6P 345262-58-0P 345262-61-5P
 345262-81-9P 345262-84-2P 345262-97-7P
 345263-04-9P 345263-21-0P 345263-24-3P
 345263-27-6P 345263-31-2P 345263-36-7P
 345263-90-3P 345263-92-5P 345263-95-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of 11H,12H,14H-pyrrolo[3,4-c]quinolino[8',8a',1':3,2,1]-pyrrolo[2,3-a]carbazole-5,7-diones for the treatment of proliferative diseases)

RN 345262-54-6 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[(3R)-1,2,3,4-tetrahydro-3-(hydroxymethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 345262-58-0 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid, 7-[2,5-dihydro-4-(1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-3-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 345262-61-5 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[2,5-dihydro-4-(1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-3-
[(4-hydroxyphenyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 345262-81-9 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[2,5-dihydro-4-(1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 345262-84-2 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[4-(6-fluoro-1H-indol-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-
dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 345262-97-7 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[2,5-dihydro-4-(1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-3-[4-[[(1,1-
dimethylethoxy)carbonyl]methylamino]butyl]-3,4-dihydro-, 1,1-dimethylethyl
ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 345263-04-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 345263-21-0 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid, 7-[2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 345263-24-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[2,5-dihydro-2,5-dioxo-4-(5-phenoxy-1H-indol-3-yl)-1H-pyrrol-3-yl]-3,4-
dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 345263-27-6 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[4-(5,6-difluoro-1H-indol-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-
3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 345263-31-2 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[2,5-dihydro-2,5-dioxo-4-[6-(trifluoromethyl)-1H-indol-3-yl]-1H-pyrrol-3-yl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 345263-36-7 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[2,5-dihydro-2,5-dioxo-4-[7-[2-[[tris(1-methylethyl)silyl]oxy]ethyl]-1H-indol-3-yl]-1H-pyrrol-3-yl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)




RN 345263-90-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[2,5-dihydro-2,5-dioxo-4-[7-[3-[[tris(1-methylethyl)silyl]oxy]propyl]-1H-
indol-3-yl]-1H-pyrrol-3-yl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)




RN 345263-92-5 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[2,5-dihydro-2,5-dioxo-4-[6-[3-[[tris(1-methylethyl)silyl]oxy]propyl]-1H-
indol-3-yl]-1H-pyrrol-3-yl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)



RN 345263-95-8 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[2,5-dihydro-2,5-dioxo-4-[7-[[[tris(1-methylethyl)silyl]oxy]methyl]-1H-
indol-3-yl]-1H-pyrrol-3-yl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)



IT 345262-53-5P 345262-62-6P 345263-13-0P

345263-30-1P 345263-37-8P 345263-99-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) .


(preparation of 11H,12H,14H-pyrrolo[3,4-c]quinolino[8',8a',1':3,2,1]-pyrrolo[2,3-a]carbazole-5,7-diones for the treatment of proliferative diseases)

RN 345262-53-5 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[2,5-dihydro-4-(1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-3-[(1,1-
dimethylethoxy)methyl]-3,4-dihydro-, 1,1-dimethylethyl ester, (3R)- (9CI)


(CA INDEX NAME)

Absolute stereochemistry.



RN 345262-62-6 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[1,2,3,4-tetrahydro-3-[(4-hydroxyphenyl)methyl]pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 345263-13-0 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-3-propanoic acid, 7-[2,5-dihydro-4-(1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-tetrahydro-2-[(phenylmethoxy)carbonyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 345263-30-1 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[2,5-dihydro-2,5-dioxo-4-[5-(phenylmethoxy)-1H-indol-3-yl]-1H-pyrrol-3-yl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 345263-37-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[7-(2-hydroxyethyl)-1H-indol-3-yl]-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 345263-99-2 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(1,2,3,4-tetrahydro-3-methylpyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)



IT 345265-01-2 345265-39-6 345265-42-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 11H,12H,14H-pyrrolo[3,4-c]quinolino[8',8a',1':3,2,1]-pyrrolo[2,3-a]carbazole-5,7-diones for the treatment of proliferative diseases)
 RN 345265-01-2 CAPLUS
 CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-3-propanoic acid, 7-[2,5-dihydro-4-(1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-2-[(1,1-dimethylethoxy)carbonyl]-1,2,3,4-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 345265-39-6 CAPLUS


CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-3-propanoic acid,
7-[2,5-dihydro-4-(1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-1,2,3,4-
tetrahydro-2-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 345265-42-1 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[4-(5-fluoro-1H-indol-3-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-
dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:453056 CAPLUS

DOCUMENT NUMBER: 135:61238

TITLE: Preparation of maleimide and carbazole derivatives for the treatment of proliferative diseases

INVENTOR(S): Al-Awar, Rima Salim; Hecker, Kyle Andrew; Huang, Jianping; Joseph, Sajjan; Ray, James Edward; Waid, Philip Parker

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 110 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001044235	A2	20010621	WO 2000-US33274	20001218
WO 2001044235	A3	20020117		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1250334	A2	20021023	EP 2000-989233	20001218
EP 1250334	B1	20040519		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 267194	T	20040615	AT 2000-989233	20001218
ES 2220585	T3	20041216	ES 2000-989233	20001218
US 2003092676	A1	20030515	US 2002-130801	20020521
US 6743785	B2	20040601		
PRIORITY APPLN. INFO.:			US 1999-171219P	P 19991216
			US 1999-171269P	P 19991216
			WO 2000-US33274	W 20001218
OTHER SOURCE(S):			MARPAT 135:61238	
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; A, B = O, S; X, Y = H; or X and Y, taken together, form a bond; R1 = H, alkyl; R5, R51 = halo, CN, alkyl, etc.; R6, R61 = alkyl; R7, R71 = alkoxycarbonyl, (CH₂)_mZ; Z = halo, OH, CO₂H, etc.; Q1, Q6 = O, Son, (CH₂)₁₋₃; Q2, Q5 = carbon-carbon single or double bond, NH, etc.; Q3, Q4 = (CH₂)₁₋₃; m = 0-5; n = 0-2], useful for inhibiting CDK4, were prepared and formulated. E.g., a multi-step synthesis of II.HCl which showed activity (0.6051 μ M) in assay of cyclin D1-cdk4 kinase with the ING peptide as substrate, was given. Some of compds. I were found to inhibit cell growth and to inhibit Rb (retinoblastoma protein) phosphorylation.


IT 345334-01-2P 345334-09-0P 345334-21-6P
345334-33-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of maleimide and carbazole derivs. for the treatment of proliferative diseases)


RN 345334-01-2 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid, 7-[4-(5,6-dihydro-5,5-dimethyl-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 345334-09-0 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid, 7-[4-(8-fluoro-5,6-dihydro-6,6-dimethyl-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 345334-21-6 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-[4-(5,6-dihydro-6,6-dimethyl-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-2,5-
 dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-, 1,1-dimethylethyl ester
 (9CI) (CA INDEX NAME)



RN 345334-33-0 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
 7-[4-(5,6-dihydro-4,4-dimethyl-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-2,5-
 dihydro-2,5-dioxo-1H-pyrrol-3-yl]-3,4-dihydro-, 1,1-dimethylethyl ester
 (9CI) (CA INDEX NAME)




IT 345334-03-4P 345334-13-6P 345334-25-0P
 345334-37-4P 345334-45-4P 345334-49-8P
 345334-53-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of maleimide and carbazole derivs. for the treatment of proliferative diseases)


RN 345334-03-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(5,6-dihydro-5,5-dimethyl-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 345334-13-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(8-fluoro-5,6-dihydro-6,6-dimethyl-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 345334-25-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(5,6-dihydro-6,6-dimethyl-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 345334-37-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(5,6-dihydro-4,4-dimethyl-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)- (9CI) (CA INDEX NAME)



RN 345334-45-4 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(5,6-dihydro-5,5-dimethyl-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 345334-49-8 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(8-fluoro-5,6-dihydro-6,6-dimethyl-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 345334-53-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(5,6-dihydro-4,4-dimethyl-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1,2,3,4-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 345337-08-8

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of maleimide and carbazole derivs. for the treatment of
proliferative diseases)

RN 345337-08-8 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-2(1H)-carboxylic acid,
7-[4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-2,5-dihydro-2,5-dioxo-
1H-pyrrol-3-yl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX
NAME)



ANSWER 12 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:167995 CAPLUS

DOCUMENT NUMBER: 134:207833

TITLE: Preparation of tricyclic inhibitors of poly(ADP-ribose) polymerases

INVENTOR(S): Webber, Stephen Evan; Skalitzky, Donald James; Tikhe, Jayashree Girish; Kumpf, Robert Arnold; Marakovits, Joseph Timothy; Eastman, Walter Brian

PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., USA; Cancer Research Campaign Technology Limited

SOURCE: PCT Int. Appl., 236 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001016136	A2	20010308	WO 2000-US23882	20000831
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2382404	A1	20010308	CA 2000-2382404	20000831
AU 200073389	A	20010326	AU 2000-73389	20000831
AU 781826	B2	20050616		
EP 1208104	A2	20020529	EP 2000-961437	20000831
EP 1208104	B1	20050119		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR 2000015051	A	20020625	BR 2000-15051	20000831
HU 200202703	A2	20021228	HU 2002-2703	20000831
JP 2003513015	T	20030408	JP 2001-519702	20000831
US 6548494	B1	20030415	US 2000-653184	20000831
EE 200200100	A	20030616	EE 2002-100	20000831
NZ 516793	A	20040326	NZ 2000-516793	20000831
AT 287406	T	20050215	AT 2000-961437	20000831
PT 1208104	T	20050429	PT 2000-961437	20000831
ES 2234657	T3	20050701	ES 2000-961437	20000831
AP 1553	A	20060228	AP 2002-2449	20000831
W: GM, GH, KE, LS, MW, MZ, SL, SD, SZ, TZ, UG, ZW				
NO 2002000421	A	20020425	NO 2002-421	20020128
NO 322475	B1	20061009		
ZA 2002000830	A	20030130	ZA 2002-830	20020130
IN 2002MN00171	A	20050318	IN 2002-MN171	20020211
MX 2002PA02138	A	20030820	MX 2002-PA2138	20020227
BG 106562	A	20030331	BG 2002-106562	20020329
HK 1045509	A1	20050429	HK 2002-106977	20020925
PRIORITY APPLN. INFO.:			US 1999-152142P	P 19990831
			WO 2000-US23882	W 20000831
OTHER SOURCE(S):		MARPAT 134:207833		
GI				



- AB The title compds. [I; X = O, S; Y = N, CR3 (wherein R3 = halo, CN, alkyl, etc.); R1 = H, halo, CN, etc.; R2 = H, alkyl; R4 = H, halo, alkyl; R5-R8 = H, alkyl, alkenyl, aryl, etc.] which are poly(ADP-ribosyl)transferase inhibitors, and are useful in treating cancers and in ameliorating the effects of stroke, head trauma, and neurodegenerative disease, were prepared E.g., a multi-step synthesis of 1-phenyl-8,9-dihydro-7H-2,7,9a-triaza-benzo[cd]azulen-6-one [I; Y = N; X = O; R1 = Ph; R2, R4-R8 = H] was given. Biol. data for compds. I were presented.
- IT 328542-78-5P 328545-08-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of tricyclic inhibitors of poly(ADP-ribose) polymerases)
- RN 328542-78-5 CAPLUS
- CN Pyrrolo[3,2,1-jk][1,4]benzodiazepin-1(2H)-one, 3,4-dihydro-6-(2-pyridinyl)-(9CI) (CA INDEX NAME)



- RN 328545-08-0 CAPLUS
- CN Pyrrolo[3,2,1-jk][1,4]benzodiazepin-1(2H)-one, 6-(4-fluorophenyl)-3,4-dihydro-7-(1H-pyrazol-3-yl)-(9CI) (CA INDEX NAME)



10/506,459

=> => d his

(FILE 'HOME' ENTERED AT 12:42:37 ON 09 AUG 2007)

FILE 'REGISTRY' ENTERED AT 12:42:55 ON 09 AUG 2007

L1 STRUCTURE UPLOADED

L2 10 S L1

L3 564 S L1 SSS FUL

L4 493 S L3 AND CAPLUS/LC

L5 71 S L3 NOT L4

FILE 'CAPLUS' ENTERED AT 12:44:29 ON 09 AUG 2007


L6 12 S L3

FILE 'REGISTRY' ENTERED AT 12:45:12 ON 09 AUG 2007



=> d 15 71

10/506,459

L5 ANSWER 71 OF 71 REGISTRY COPYRIGHT 2007 ACS on STN
RN 603279-00-1 REGISTRY
ED Entered STN: 13 Oct 2003
CN 1H-Pyrrole-2,5-dione, 3-(7-chloroimidazo[1,2-a]pyridin-3-yl)-4-[1,2,3,4-tetrahydro-2-(1-methylethyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-(9CI) (CA INDEX NAME)
MF C25 H22 Cl N5 O2
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



chain nodes :

14

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13

ring bonds :

1-2 1-7 2-3 3-4 3-8 4-5 4-11 5-6 5-13 6-7 8-9 9-10 10-11 11-12 12-13

exact/norm bonds :

1-2 1-7 2-3 3-4 3-8 4-5 4-11 5-6 5-13 6-7 8-9 9-10 10-11 11-12 12-13

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom
13:Atom 14:Atom 15:CLASS